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Poxviruses produce two morphologically distinct infectious particles, mature 
virions (MVs) and extracellular virions (EVs). During replication, some MVs 
differentiate and become wrapped with cellular membranes, transported to the 
periphery, and exported as EVs. Some orthopoxviruses, e.g., cowpox virus (CPXV), 
form large, discrete cytoplasmic inclusions called A-type inclusion bodies (ATIs) 
within which MVs are embedded by a process called occlusion. ATIs are composed of 
aggregates of the A-type inclusion protein (ATIp), which is truncated in 
orthopoxviruses such as vaccinia virus (VACV) that fail to form ATIs. VACV does 
encode a functional A26p, which along with the ATIp is required for occlusion. A26 
lacks a transmembrane domain, and nothing is known regarding how it associates 
with the MV and regulates occlusion. Additionally, little is known about the 
formation of ATIs and how MVs become embedded within them. Here, experiments 
show that A26p is incorporated into MVs by the A27p-A17p complex and interacts 
  
with A25p, a truncated form of the CPXV ATIp. Restoration of the full-length ATI 
gene is sufficient for VACV ATI formation and the occlusion of MVs. A26p directly 
interacts with ATIp, and this interaction, as well as the A26p-A27p interaction, are 
required for occlusion. The data demonstrates that ATI mRNAs are transported out of 
viral factories (VFs) and translated in the cytoplasm. ATIs enlarge both by new 
protein synthesis and by coalescence, which requires microtubules. ATIs do not 
nucleate around MVs but rather MVs move along microtubules to embed within 
ATIs. Taken together, the data suggest a model for occlusion in which MVs move 
along microtubules to ATIs that are translated from mRNAs in the cytoplasm. At the 
ATIs, A26p has a bridging role between ATIp and A27p, and A27p provides a link to 
the MV membrane. Although the specificity of A26p for MVs suggested A26p might 
regulate wrapping, I did not detect an effect of either the deletion of A26 or occlusion 
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Chapter 1: Review of literature 
 
1.1 The Poxviridae 
1.1.1 Classification  
The family Poxviridae has large double-stranded DNA genomes and is 
distinguished by a replication cycle that occurs entirely in the cytoplasm of infected 
cells and an unique, complex virion architecture. Poxviruses have been grouped with 
other large eukaryotic DNA viruses (genomes > 100 kbp) that replicate exclusively or 
partially in the cytoplasm called the Nucleo-Cytoplasmic Large DNA Viruses 
(NCLDV). The NCLDVs are comprised of diverse families including poxviruses, 
asfarviruses, iridoviruses, phycodnaviruses [1], mimiviruses [2], and marseillevirus 
[3] that likely share a common viral ancestor [1]. The family Poxviridae can be 
divided taxonomically into two subfamilies, the Entomopoxvirinae and the 
Chordopoxvirinae. The Entomopoxvirinae infect insects and are subdivided into the 
genera Alphaentomopoxviruses, Betaentomopoxviruses, and Gammaentomo-
poxviruses [4]. The Chordopoxvirinae infect diverse vertebrate species including 
mammals, birds, and reptiles and are comprised of eight genera: Suipoxvirus, 
Avipoxvirus, Capripoxvirus, Leporipoxvirus, Molluscipoxvirus, Orthopoxvirus, 
Parapoxvirus, and Yatapoxvirus. Classification of poxvirus species within genera is 
based on criteria such as particle morphology, antigenic relatedness, genetic 







The Orthopoxvirus genus has a broad tropism and includes important causes 
of disease in humans [5]. Species in the Orthopoxvirus genus include the camelpox, 
cowpox, ectomelia, monkeypox, taterapox, vaccinia, and variola viruses. The most 
significant members of the Orthopoxvirus genus in human disease include variola 
virus (VARV), monkeypox virus (MPXV), and vaccinia virus (VACV). VARV is the 
most prominent of the orthopoxviruses as it is the causative agent of smallpox, a 
historically devastating disease. Smallpox was eradicated in 1977 through worldwide 
vaccination effort using a strain of another important orthopoxvirus, VACV. Despite 
eradication, VARV is rated as one of the top bioterrorism threats by the US Centers 
for Disease Control and Prevention (CDC) and efforts continue to develop a more 
efficacious vaccine and new antivirals. MPXV is an emerging important zoonotic 
disease because there is no proven treatment for the disease in human infections, and 
human-to-human transmission of MPXV has occurred [6]. In addition to serving as 
the vaccine against VARV, VACV has become extremely useful as a potential tool 
for the development of recombinant vaccines, and advancements in molecular 
biology have been made through genetic and biochemical studies of aspects of the 
VACV life cycle. VACV is the most characterized of the poxviruses and most of our 
understanding of poxvirus biology comes from studies on VACV [5].  
1.1.3 Virion structure  




defined structures such as glycoprotein spikes that characterize other types of viruses. 
Instead, poxvirus virions are highly asymmetric, brick-shaped particles and are one of 
the largest viruses at about 360 X 270 X 250 nm in size (Figure 1-1)[7-9]. Moreover, 
poxviruses produce three types of particles, mature virions (MV), wrapped virions 
(WV), and extracellular virions (EV), that differ from one another in the number of 
surrounding envelopes and the protein composition associated with those envelopes. 
The most abundant particle produced during infection, the MV, is predominantly 
protein by dry weight with ~3.2% DNA and ~5% lipid [10] and trace amounts of 
RNA, spermine, and spermidine [5]. MV particles consist of a dumbbell-shaped core 
surrounded by a single lipoprotein membrane [5] of about 5-6 nm in thickness [9]. 
Under the lipoprotein membrane, two lateral densities with an unknown function 
called lateral bodies are located in the concavites of the dumbbell core [5]. The core 
consists of two layers that together are about 18 nm in thickness surrounding an inner 
cavity that contains nucleoprotein [9].  
1.1.4 Genome organization  
 Poxviruses have double-stranded linear DNA genomes that range from 143-
300 kbp [5]. About 100 genes are conserved among the chordopoxviruses, and about 
50 of them are also conserved in entomopoxviruses. Despite variability in genome 
size and nucleotide sequences, the structure of poxvirus genomes as well as the 
organization of ORFs within the genomes are conserved. The VACV genome is 195 
kbp and contains ~200 ORFs [11]. The most variable genes are found at the ends of 
the genome and typically encode proteins involved in host-interactions [5]. VACV 







Figure 1-1. Mature virion morphology. The left panel shows a scanning electron 
micrograph of a mature virion. Virions lack symmetry and prominent, distinct 
structural features. The right panel is a transmission electron micrograph of a mature 
virion showing a brick-shaped particle surrounded by a single lipoprotein membrane 
with a condensed core structure. Scale bars, 50 nm. Images were generously provided 


























identical nucleotide sequences in opposite orientations [12, 13]. The genome 
terminates with an A/T rich region that forms a covalently closed hairpin loop that 
links the two DNA strands [14]. The central region of the genome contains conserved 
genes that encode proteins involved in essential processes such as transciption, 
replication, and virus assembly [5]. Most poxvirus genes are non-overlapping, and 
each ORF has an upstream promoter that regulates transcription at early, 
intermediate, or late times during infection. The ORFs have different transcriptional 
orientations and are transcribed rightward (R) leftward (L) from the genome.  
1.1.5 Genome nomenclature  
VACV genes are named based on both their location in the genome as 
determined by restriction mapping using the restriction endonuclease Hind III and 
their transcriptional orientation [11]. Hind III-digestion of VACV strain Western 
reserve (WR) genome yields 15 digested products named by mobility in agarose gels. 
The fragments are designated A-O, with A being the largest and O the smallest [15]. 
The ORFs are numbered based on the positions from left to right within the digested 
fragments, and the transcriptional orientation from left to right (R) or right to left (L) 
is designated. For example, the A26L gene is the 26th ORF in the A Hind III fragment 
and is transcribed from right to left (L). The gene and protein names are typically the 
same except that the protein name lacks the transcriptional orientation, and for further 
clarification, I have included a “p” to designate the protein product of a gene. For 






1.2 Virus Replication 
1.2.1 Attachment and entry  
VACV infects numerous cell types and several different animal species. 
Although both MV and EV particles are infectious, EVs must first shed the outer 
membrane to expose the entry-fusion complex (EFC), which is located in the MV 
membrane [16]. The processes leading to the release of viral cores into the cytoplasm 
can be delineated into two steps: attachment and entry (Figure 1-2). Four VACV 
proteins have been identified as important in mediating virus attachment A27p, D8p, 
H3p, and A26p. A27p, D8p, and H3p bind glycosoaminoglycans [17-19], while A26p 
binds the extracellular matrix protein laminin [20]. Attachment is generally 
considered important for tethering virions to the cell surface for signaling and uptake, 
but individual deletions of the VACV genes encoding attachment factors does not 
prevent cell entry [21]. 
VACV can enter cells by low pH induced fusion from within endosomes [22-
24] or by fusion at the plasma membrane [21]. Entry requires the coordination of 
several MV-membrane proteins that are associated with or form a complex known as 
the entry-fusion complex (EFC) [25]. There are 9 integral EFC proteins (A16p [26], 
G9p [27], A21p [28], A28p [29], G3p [30], H2p [31], J5p [25], L5p [32], and O3p 
[33])  all of which are required for entry. L1p and F9p are associated with the EFC 
and are also required for entry [34, 35]. The I2 protein is required for entry, although 
it has not yet been shown to be part of the EFC [36]. The specific roles of the EFC 
proteins at different stages during the entry process are not known and a specific 













Figure 1-2. Replication cycle of VACV. Schematic of the VACV replication cycle 
with numbered and color-coded steps : pre-replicative (blue), post-replicative 
(salmon), and morphogenesis (purple). events highlighted in blue or salmon, 
respectively. Morphogenesis is highlighted in purple. (1) MV enter by fusion at the 
plasma membrane or within endosomes delivering the core into the cytoplasm. (2) 
Early mRNAs are synthesized within the cores and extruded into the cytoplasm. (3) 
Early mRNAs encode proteins required for replication of the DNA genome and the 
initiation of intermediate transcription. (4) The viral genome is uncoated and (5) 
replicates by a rolling hairpin mechanism that generates concatemers. (6) Replication 
occurs within viral factories, which also coordinate intermediate 
transcription/translation, late transcription/translation, and assembly of MVs. (7) 
Intermediate transcription occurs after genome replication and (8) late transcription 
factors are translated from intermediate mRNAs. (9) Late transcription factors 
regulate the transcription of late mRNA, which (10) is translated into early 
transcription factors and structural proteins that become packaged into virions. (11) 
Crescent membranes are the first morphogenesis intermediates distinguishable by 
electron microscopy. (12) Crescents grow and surround genomes and viral proteins 
forming spherical immature virions (IV). (13) IV condense and undergo complex 
changes to form the brick-shaped mature virion (MV). (14) A subset of MVs become 
doubly membrane wrapped at either the trans-Golgi network or endosomal cisternae 
to form wrapped virus (WV), which have three viral membranes. (15) WV traffic 
along microtubules to the plasma membrane where the outer membrane fuses 
releasing the extracellular virus (EV). (16) EV that remain on the surface of the cell 
are called cell-associated EV or CEV and they can polymerize actin tails to propel 





plasma membrane or from within endocytic vesicles, the MV membrane is lost and 
viral cores are released into the cytoplasm to initiate virus infection. 
1.2.2 Virus gene expression  
VACV gene expression is temporally regulated and genes can be classed as 
pre- and post-replicative depending on whether expression occurs before or after 
DNA replication, respectively (Figure 1-2)[5]. The pre-replicative class includes early 
genes, and the post-replicative class includes intermediate and late genes. Global 
analysis of the VACV transcriptome revealed the production of 118 pre-replicative 
ORFs and 93 post-replicative ORFs [38]. In general, early genes express proteins 
required for early functions such as nucleotide biosynthesis and DNA replication as 
well as proteins that combat host-defense mechanisms. Intermediate and late genes 
encode proteins required for later functions such as virion assembly and 
morphogenesis. 
Each class of genes also has a conserved stage-specific promoter sequences 
that temporally regulates their expression [39-41]. All VACV genes are transcribed 
by a multisubunit DNA-dependent RNA polymerase (RPO) that is comprised of at 
least 8 core proteins. Additionally, each stage encodes accessory transcription factors 
required for initiation of transcription of the subsequent class of genes. Early gene 
products are required for the transcription of intermediate genes, the products of 
which are required for late gene transcription. Late genes, in turn, encode 
transcriptional regulatory factors necessary for early transcription, which are 
packaged along with the viral genome into virion cores for the initiation of early gene 




Following entry, cores associate with microtubules and move to sites within 
the cytoplasm where early gene transcription occurs [43, 44]. Synthesis of early 
mRNAs can occur within minutes of infection, and early mRNAs are extruded from 
pores in the core. The early transcription apparatus includes the VACV RPO, an 
RNA-polymerase associated protein of 94 kDa (Rap94), the VACV early 
transcription factor (VETF), capping and methylating enzymes, poly(A) polymerase, 
topoisomerase, and two nucleic acid-dependent ATPases [5]. The stage-specific 
transcriptional regulatory factors for early transcription include Rap94 and VETF. 
Rap94 interacts with the RPO and possibly prevents transcription from intermediate 
and late promoters. Rap94 also interacts directly with VETF [45], which is a 
heterodimer with ATPase and DNA-binding activities that binds early promoters. 
Cessation of early transcription follows dissociation of the core, which is thought to 
dismantle the early gene transcription apparatus [5]. 
Intermediate transcription requires DNA replication [46], intermediate 
promoter sequences, and is mediated by viral intermediate transcription factors 
(VITF) (VITF-1, VITF-2, VITF-3 [47]), capping enzyme, and the RPO. VITF-1 and 
VITF-3 are virally encoded, whereas VITF-2 is cellular [47, 48]. VITF-1 is encoded 
by the VACV E4L gene and also functions as an RPO subunit, and VITF-3 is a 
heterodimer of proteins encoded by the VACV A8R and A23R genes [47]. VITF-2 
activity is complemented by the Ras-GTPase-activating protein SH3 domain-binding 
protein (G3BP) and/or p137, the cytoplasmic activation/proliferation-associated 
protein-1 [48].  




throughout the remainder of the virus life cycle. Initiation of transcription requires the 
viral RPO, three intermediate proteins, one early protein, and a cellular protein. The 
intermediate genes G8L, A1L, and A2L encode the VACV late transcription factors 
(VLTFs) VLTF-1, VLTF-2, and VLTF-3, respectively, which represent the minimal 
viral proteins required for late transcription [46]. Additionally, the early H5R gene 
product [49] and the host protein VLTF-X [50] stimulate late transcription. Purified 
nuclear riboproteins A2/B1 and RBM3 can complement VLTF-X function 
individually or together in vitro [51]. VLTF-X co-purifies with a late promoter DNA-
binding activity, and none of the viral VLTFs bind late promoters suggesting 
recruitment of VLTFs and the RPO to late promoters might be mediated by a host 
factor [42].  
VACV mRNAs have a 5’ cap and are 3’polyadenylated. However, both the 5’ 
and 3’ ends of the different temporal classes have unique features. About half of the 
VACV genes have an early promoter [52], which consists of the consensus core 
sequence AAAAAATGAAAAAA/TA [40] separated by 12-17 nucleotides from a 
downstream initiator element, which is an A or G residue. In contrast, both 
intermediate and late transcripts have initiator elements that result in the production 
of mRNAs that have a 5’poly(A) leader sequence up to 30-40 nucleotides in length 
[53]. Intermediate transcription core promoters are AT rich 14 bp sequences that are 
10 or 11 bp upstream from the initiator element, TAAA. Late promoters consist of a 
20 bp, A-T rich core and a downstream initiator element, TAAAT that is often 
followed by G nucleotide, TAAATG. The ATG in the initiator element often serves 




initiator  elements of both intermediate and late promoters, and additional A residues 
are added by a slippage mechanism to form a 5’ poly(A) leader [54]. Slippage is 
thought to occur by the stuttering of the polymerase at the A triplets found in the 
TAAA initiator element of intermediate promoters and the TAAAT in late promoters.  
 The early gene mRNAs are distinguished from the other classes by 
homogenous 3’ends. The 3’ends of early mRNAs are generated by regulated 
transcriptional termination, which occurs 20-50 nucleotides downstream of the signal 
sequence UUUUUNU [55, 56]. Unlike early mRNAs, both intermediate and late 
mRNAs lack a conserved termination signal sequence and therefore have 
heterogenous 3’ ends [57]. Interestingly, four late mRNAs have been shown to have 
unique homogenous 3’ends: telomeric transcripts from vaccinia virus [58], transcripts 
from the gene encoding the second largest subunit of RNA polymerase (A24R) in 
vaccinia virus [59], transcripts from the F17R gene [60], and transcripts from the 
gene encoding the major protein component of the A-type inclusion (ATI) bodies 
[59]. The mechanism of 3′ end formation of the telomeric transcripts and the A24 
transcripts has not been shown, but the ends of the F17R and ATI transcripts are 
generated by site-specific cleavage of a precursor RNA [60, 61].  
The site-specific cleavage of the ATI mRNA is mediated by a 43-nucleotide 
RNA cis-acting element and the resulting ends are 3’ polyadenylated. The cis-acting 
element is composed of at least two noncontiguous regions with a spacer region of 10 
bases whose composition may be changed without interfering with RNA 3′ end 
formation. The sub-element containing the cleavage site is upstream of the other sub-




the other cleavage element and they do not resemble the ATI mRNA elements in 
sequence. Portions of the two noncontiguous regions are complementary to each 
other, suggesting the possibility that the two regions form a specific structure that 
participates in 3′ end formation [62]. The cleavage site in the F17R transcript does not 
have sequence homology or predicted structural homology to the ATI cleavage sites, 
however, the H5 protein has been implicated as the cleavage factor for both 
transcripts [60]. 
Each RNA class exhibits rapid turnover following synthesis. Recently, it was 
shown that two viral de-capping enzymes, D9p and D10p, remove the 5’ cap 
destabilizing viral transcripts [63, 64]. D9 is regulated by an early promoter and D10 
is regulated by a late promoter [65, 66]. In addition to a role in the regulation of viral 
mRNAs, D9 and D10 de-capping and destabilization of host transcripts likely 
contributes to the shutdown in host protein synthesis. 
1.2.3 Virus genome replication  
Unlike most DNA viruses, poxviruses replicate their double stranded DNA 
genomes entirely in the cytoplasm of infected cells (Figure 1-2). Therefore, the 
majority of the proteins required for replication are virally encoded early proteins. 
VACV replication occurs in discrete, juxtanuclear bodies called viral factories (VF) 
and initiates between 1-2 h post-infection, following disassembly of the core [5]. 
Proteins important for VACV replication and processing of viral DNA include the 
following: DNA polymerase encoded by E9L, primase/NTPase encoded by D5R [67, 
68], uracil DNA glycosylase encoded by D4R [69], processivity factor encoded by 




A22R [70]. Poxviruses also encode enzymes involved in the synthesis of 
deoxyribonucleotides such as a thymidine kinase, thymidylate kinase, ribonucleotide 
reductase, and dUTPase. None of these precursor metabolism enzymes is essential for 
replication in cell culture, although deletion of the thymidine kinase and 
ribonucleotide reductase genes attenuates infection in vivo [5]. 
Replication is poorly understood, but is thought to proceed by a rolling 
hairpin, strand displacement mechanism [5]. In this model, one of the hairpin termini 
becomes nicked providing a primer for leading strand DNA synthesis in the 5’ to 3’ 
direction [71]. Replication results in head-to-head and tail-to-tail concatemerized 
genomes that get resolved following late gene synthesis of the resolvase, A22p. There 
are also findings that suggest lagging strand synthesis might be occurring. Small 
DNA fragments covalently linked to RNA have been reported suggestive of the 
existence of Okazaki fragments [72]. The VACV D5 protein was demonstrated to 
have primase activity [68, 73], and the VACV ligase encoded by the A50R gene was 
shown to be required for viral DNA replication in cells in which cellular ligases were 
knocked down [74]. 
1.2.4 Virus factories  
Poxviruses replicate their genomes, transcribe intermediate and late genes, 
translate intermediate and late mRNAs, and assemble progeny virions within 
specialized compartments called viral factories or VFs (Figure 1-2) [75-78]. Each VF 
arises from one infectious virion [78, 79]. After entry, cores move along microtubules 
and accumulate at the cytosolic side of rough-ER membranes where the genome is 




become surrounded in ER-derived cisternae [80, 81]. Cytoplasmic VFs are visible by 
electron microscopy as early as 3 hpi and are amorphous electron-dense regions 
containing nucleic acid and devoid of organelles (Figure 1-3A). Confocal microscopy 
of DAPI-stained VFs shows compact bodies that expand in size during the course of 
infection presumably due to an increase in the amount of genomic DNA (Figure 1-
3B) [79, 80, 82]. During expansion, VFs migrate to juxtanuclear locations along 
microtubules, and VFs can collide and fuse together during this migration [82]. By 5 
hpi, at the onset of virion assembly, the ER envelope begins to disassemble. DAPI 
staining reveals that VFs lose their compact appearance and begin to dissipate during 
the course of infection presumably because genomic DNA is being packaged into 
virions.  
A recent study showed that VFs coordinate genome replication with 
transcription and translation as well as virus assembly [79]. In contrast to early 
mRNA transcription,which takes place inside cores, intermediate and late mRNAs  
are transcribed and translated within VFs [44, 79]. DAPI staining revealed VFs are 
not uniform masses but instead have tunnel-like cavities giving them a ‘sponge’-like 
appearance. The cavities appear to connect with the cytoplasm resulting in the 
increase of the cytoplasm-factory interface area. The viral mRNA as well as viral and 
host intermediate transcription factors A23p and Ras-GTPase-activating protein SH3 
domain-binding protein (G3BP), respectively, localized to these tunnel-like cavities 
or subdomains within the VFs. It was also shown that transcription is intimately 
associated with translation within the VF subdomains. Confocal microscopy revealed 





Figure 1-3. Viral factories. (A) Transmission electron micrograph of VACV viral 
factory (boxed) containing morphogenesis intermediates early post infection. Scale 
bar, 500 nm. (B) Images show two infected cells with A4p:YFP in viral factories 
(arrowheads). HeLa cells were infected with a recombinant VACV expressing YFP 




RNA were coincident with G3BP in the cavities [79]. Additionally, staining with 
antibodies to the P proteins of the large ribosomal subunit showed the presence of 
ribosomes in VFs. Finally, experiments in which cells were infected with two 
different recombinant VACVs, each expressing a different fluorescent protein (CFP 
and YFP) fused to a late viral protein, resulted in individual cyan or yellow VFs in the 
same cell. This showed that transcription and translation occur from the input virus 
genome within the boundary of the VF [79].  
1.2.5 Mature virion morphogenesis  
Poxviruses undergo an intricate assembly process that yields two infectious 
virions that are morphologically distinct, MVs and EVs (Figure 1-4)[77, 83]. 
Morphogenesis begins with a growing crescent-shaped membrane supported by a 
protein lattice. Crescents envelope the genome along with core protein precursors and 
seal becoming immature virions (IV), which in turn lose the support and mature into 
infectious, mature virions (MV). MV acquire two additional membranes forming the 
intracellular wrapped virus (WV) and following egress and fusion at the plasma 
membrane the outer membrane is lost to release the doubly wrapped EVs and CEVs 
(Figure 1-2). 
Assembly begins in the VF roughly 4 hpi [83], and the first distinct structures 
visualized by electron microscopy are crescent-shaped precursors and immature 
virions (IVs)(Figure 1-4)[84]. The composition and origin of crescents is disputed, 
but they are most likely single-membrane structures. Although recent work suggests 
they might be derived from ER membranes [85, 86], there is no direct evidence 






Figure 1-4. Transmission electron micrographs of different stages during VACV 
virion morphogenesis. (C) Crescents; (IV) immature virion; (Nu) nucleoid; (MV) 
mature virion; (WV) wrapped virion; (EV) extracellular virion. Arrows indicate 
membranes. The MV has one membrane, which is also present WVs and EVs. The 
WV has three membranes, and the EV has two membranes having lost the outer 














lattice coat comprised of trimers of the D13 protein arranged on the membrane 
surface in a honeycomb lattice that appear as electron-dense ‘spicules’ by electron 
microscopy [87, 88]. Crescents envelope viroplasm forming 300 nm, spherical IVs 
Following loss of the supportive protein lattice, IVs condense and mature into the 
brick-shaped, infectious MV particles.  
Electron microscropic studies of conditional lethal VACV mutants have 
identified several viral proteins required for crescent formation. Repression of two 
viral membrane proteins, A14p and A17p, demonstrated their requirement for 
crescent formation. A17p is a transmembrane protein that spans the viral membrane 
twice with both termini extending into the cytoplasmic face of the membrane and a 
hydrophilic loop within the lumen [89, 90]. The N-terminus of A17p binds and 
recruits D13p, which forms a lattice that likely confers stability and curvature [87, 88, 
91]. Repression of soluble proteins H5p [92], G5p [93], A11p [94], H7p [95], and 
F10p [96-98] also results in an absence of crescent-shaped membranes. F10p is a dual 
specificity kinase associated with viral membranes and is required for 
phosphorylation of the A14 and A17 proteins [99], which are transmembrane proteins 
required for membrane biogenesis. Additionally, the F10p phosphorylates the H5p 
and the A30 protein. A30p, along with F10p, G7p, J1p, D2p, D3p, and A15p are core 
proteins that form a complex that mediates the filling of crescents with viroplasm 
during IV formation [100, 101]. Before the crescent membrane grows to a closed, 
spherical IV, the genome is acquired and condenses to a ‘nucleoid’ appearing as a 
circular, electron-dense body by electron microscopy (Figure 1-4). How the genome 




or the A17 membrane protein blocks the incorporation of genomic DNA into IVs. 
Additionally, repression of the Holliday resolvase, A22p, perturbs concatemer 
resolution and results in the accumulation of IVs without nucleoids [84].   
Maturation of IVs to infectious MVs involves several processes including the 
loss of the D13p honeycomb lattice, the proteolytic processing of proteins, and the 
formation of disulfide bonds [84]. This complex process results in brick-shaped MV 
particles comprised of ~80 proteins (Figure 1-4)[84]. The loss of the D13p lattice 
requires the proteolytic processing of A17p. After IVs are formed, the N- and C-
termini of A17p are both proteolytically processed by the viral protease I7p at 
AG16↓A and AG185↓A motifs. This cleavage results in the loss of the D13p scaffold 
and the IV collapses to form the brick-shaped MV [91]. Cleavage of the core proteins 
A3p, A10p, A12p, L4p, and G7p at the consensus AG↓X motif is also required for 
maturation and is also likely mediated by the I7 protease [5]. Thus, proteolytic 
processing of at least one membrane protein (A17p) and five core proteins is required 
for the maturation of IVs to MVs. 
The formation of infectious MV also requires the modification of disulfide 
bonds in several MV-membrane proteins. Cellular disulfide bond formation occurs 
within the ER lumen, but viral proteins are exposed to the reducing cytoplasm of 
infected cells. Therefore, VACV encodes its own redox system that shows specificity 
for viral proteins localized to the viral membrane [102]. Repression of any of the 
VACV redox proteins, the E10, A2.5, and G4 proteins, results in an arrest in 
morphogenesis [103-105].  




Most MVs remain in the cell until cellular lysis and are surrounded by a single 
lipid membrane [106]. Some MVs, however, acquire two additional membranes to 
WV (Figure 1-4). Wrapped virions, in turn, traffic to the plasma membrane and 
become exocytosed, losing the outermost membrane upon release to the cell surface 
as either CEV or extracellular virions (EV)(Figure 1-4)[107]. CEVs remain attached 
to the cell surface, whereas EVs are released into the extracellular millieu. CEV and 
EV production requires several steps (Figure 1-2): (1) wrapping of MV to form WV, 
(2) WV egress to the plasma membrane, (3) fusion of the outermost WV membrane 
with the cytoplasmic leaflet of the plasma membrane, and (4) CEV dissemination by 
the polymerization of actin tails.  
MVs require microtubules for movement from VFs to sites of wrapping [108]. 
Live cell imaging of cells infected with recombinant VACV expressing the yellow 
fluorescent protein (YFP) fused to the core protein A4p showed that movement of 
MVs between VFs and sites of wrapping is bidirectional, saltatory, and disrupted by 
the microtubule depolymerizing drug nocodazole [108]. The viral protein(s) and 
molecular motor(s) involved in this MV movement are currently unknown [108, 109].  
The two additional membranes acquired for WVs are derived from either the 
trans-Golgi network (TGN) or endosomal cisternae [110, 111]. The wrapping 
membranes contain six virus-encoded proteins that are not present in MVs and 
regulate the formation of CEV and EV: F13p, B5p, A33p, A34p, A36p, and F12p 
[112-117]. A27p also regulates wrapping, but is found in both MV and EV/CEV 
particles. Repressing the expression of any of these gene products results in a small 




spread and plaque formation. Wrapping requires wrapping membrane-associated 
proteins F13p and B5p [115, 117, 118] and MV membrane-associated A27p [119]. 
F13L-, B5R-, and A27L-deletion viruses produce small plaques, and WV is not 
detected in infected cells by electron microscopy [115, 117, 119]. Disulfide-bonded 
trimers of A27p are attached to the MV membrane by protein-protein interactions 
with the MV transmembrane protein, A17p [120-122]. The A27-A17 interaction is 
mediated through C-terminus of A27p, which contains an alpha helical “anchoring 
domain [120, 123].“ The precise role of A27p in wrapping is unknown; however, EM 
studies have shown that A27p is almost exclusively associated with the cytosolic face 
of the MV membrane [124], and it is suggested that A27p might interact with the 
wrapping membrane through interactions with a virus or host protein(s). It was 
suggested that A27p might be a movement factor, but live cell imaging showed that 
MV could move bidirectionally between VFs and sites of wrapping in the absence of 
the A27p [108].  
F13p is located between the EV/CEV outer envelope and the MV membrane 
[107]. F13p lacks a transmembrane domain and is instead anchored to membranes 
through two palmitylated cysteines [125]. F13p is the target of an antiviral compound 
known as ST-246 [4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-
4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide] that inhibits EV production 
and protects mice from orthopoxvirus-induced disease [126]. The role of B5p in 
wrapping in not understood, but it contains a putative phospholipase motif that is 
essential for the production of WV and is located on the outside of the CEV/EV 




abundant in EVs, but unlike F12p it is also present in MV [128]. A study recently 
showed that F12p and E2p interact in a complex [129] and the deletion of either 
genes causes defects in WV formation resulting in a small plaque formation [128, 
129].  
WVs hijack kinesin-1 motors and traffic along microtubules during egress 
[130, 131]. WV movement requires coordination of the F12 and A36 proteins, which 
are found on the outermost envelope of WV and are not present in CEV and EV [132, 
133]. Conventionally, the A36p was considered the movement factor required for 
WV transport because A36p was shown to interact with microtubules and the deletion 
of the A36R gene blocked the recruitment of kinesin-1 motors to WVs [134, 135]. 
Subsequent studies, however, showed that A36p functions in movement by anchoring 
the movement protein, F12p, which lacks a transmembrane domain, to the WV 
particle membrane [136, 137]. F12p mimics the structure of cellular kinesin light 
chain (KLC) and this property was demonstrated to be required for the recruitment of 
the kinesin-1 motor to virions [137]. Upon reaching the cortical actin network at the 
cell periphery, A36p is phosphorylated causing WV to disassociate from kinesin-1 
motors [138], and the outer membrane of WV fuses with the plasma membrane to 
present the particle on the cell surface as CEV or result in the particles release as an 
EV [139].  
CEV can induce the formation of motile actin-containing cell projections to 
propel itself to neighboring cells [140]. The formation of these tails is abrogated when 
expression of the A36R, A33R, and A34R genes is repressed. Actin tail formation is 




membrane under CEV [107]. Phosphorylated A36p recruits cell proteins Nck, Grb2, 
N-WASP and Arp2/3 to polymerize actin beneath the CEV particle [133, 138, 141, 
142]. A36p is incorporated into wrapping membranes by A33p [133] via its 
interaction with A34p [143].  
MVs are the most abundant particles produced during VACV infections, 
although the MV to EV ratio varies among cell types and virus strains [144]. The 
mechanism by which MV differentiate to become wrapped or to remain the 
cytoplasm until lysis is unknown [145]. The MVs of some orthopoxviruses have an 
alternative fate in that they are retained in the cytoplasm within proteinaceous 
inclusion bodies. Formation of inclusion bodies and the embedment of MVs within 
them are mediated by homologs of the VACV A25 and A26 proteins, respectively. 
1.3 Virus Inclusion Bodies 
1.3.1 A-type inclusion bodies, ATIp, and A25p  
Some orthopoxviruses, including strains of cowpox (CXPV), ectromelia 
(ECTV), fowlpox, canarypox, and raccoonpox can embed MVs in cytoplasmic, 
proteinaceous matrices (Figure 1-5)[146-150]. These protein matrices were named A-
type inclusion bodies (ATIs) to distinguish them from B-type inclusion bodies, or 
VFs, formed by poxviruses for replication and assembly. When viewed by thin 
section electron microscopy ATIs appear as well-defined, circular, electron-dense 
matrices that can be several microns in diameter (Figure 1-5). ATIs form subsequent 





































Figure 1-5. Transmission electron micrograph of an A-type inclusion body 
embedded with mature virions. Scale bar, 2 µm. Image was generously provided by 










DNA replication throughout the cell and increase in size during infection [151]. 
Unlike VFs, ATIs do not contain nucleic acid and are not surrounded by membranes 
[152]. VFs and ATIs are similar, however, in that they both recruit ribosomes [79, 
152, 153]. In electron micrographs of thin-sliced sections from cells infected with 
CPXV, polyribosomes and nascent protein pulse-labeled with 3H-leucine were seen 
at the peripheries of ATIs [152, 153]. Subsequent experiments suggested that viral 
RNA was associated with the polyribosomes at surface of ATIs, but the specific RNA 
was not identified [153].  
The ATI is formed entirely by a single known viral protein, the ATIp [151]. 
The ATIp is a late protein and is one of the most abundantly synthesized proteins in 
infected cells at late stages of virus replication [151]. ATI proteins are high molecular 
weight (160 kDa in CPXV), hydrophobic proteins that contain 14 repeats of about 30 
amino acids each called the ATIp repeats [151, 154]. Orthopoxviruses that do not 
form inclusion bodies encode a truncated ATI protein that lacks these repeats. An 
ATIp homolog encoded by the A25L gene (VACVWR148) of the Western Reserve 
(WR) strain of VACV contains a deletion of two adjacent adenylate residues resulting 
in synthesis of a C-terminally truncated, 94-kDa protein [151, 155, 156]. This A25 
protein contains the N-terminal half of ATIp including the first four ATIp repeats and 
six amino acids of the fifth repeat. This protein is not sufficient for inclusion body 
formation and has no known function in VACV replication.  
1.3.2 Occlusion and A26p  
The embedment of MV within ATIs is a process referred to as occlusion. At 




matrices and encrusting the surface of ATIs (Figure 1-5)[157]. Only MVs become 
embedded and crescents and IVs are not typically seen within ATIs, although some 
IVs can be detected within them in the presence of the drug rifampicin, which blocks 
IV maturation [152]. Occlusion requires full-length homologs of the VACV A26 
protein and orthopoxviruses that do not embed MVs within ATIs have mutated A26 
genes (27, 42). Full-length A26p is 60-kDa in size, lacks predicted functional 
domains, and is expressed late during infection. A26p is somehow incorporated into 
the MV membrane although it lacks a predicted transmembrane domain [158, 159]. A 
C-terminal region of A26p shares 44% amino acid identity to the C-terminal, alpha 
helical “anchoring domain” of the A27p. A27p also lacks a transmembrane domain. 
Instead, the anchoring domain of A27p mediates protein-protein interactions with the 
transmembrane protein A17p for incorporation into the MV membrane [123]. 
Although VACV does not form inclusion bodies, the VACV A26L gene 
(VACVWR149) is intact, and the VACV A26p can complement the defective A26p 
homolog in the Brighton red (BR) strain of CPXV (CPXV-BR) [160]. 
It is unknown how A26p mediates occlusion, but it has been suggested that 
A26p might function in the retrograde movement of MVs to inclusion bodies [160]. 
In this model, MVs that lack A26p move to sites of wrapping and MVs that have 
A26p move to inclusion bodies for embedment. The main observation supporting this 
hypothesis is the spatial separation of MV from inclusion bodies seen in cells infected 
with orthopoxvirus strains expressing a truncated A26p. Additionally, an ECTV strain 
that embeds MVs within ATIs forms smaller plaques than a strain that encodes a 




previously, a small plaque phenotype is characteristic of a defect in the production of 
CEV/EV. Conversely, a large plaque phenotype could be indicative of a greater 
production CEV/EV. It was hypothesized that A26p provides an equivalent function 
in transporting VACV MVs away from sites of wrapping [160]. The VACV 
Copenhagen strain encodes a truncated A26p and was reported to produce more EV 
than the VACV IHD-J strain that encodes a full-length A26p [145]. The conservation 
of the A26L gene among orthopoxviruses irrespective of ATI formation suggests 
A26p has a function in addition to its role during MV occlusion. 
1.3.3 Insect Virus Inclusion Bodies  
Members of three diverse families of insect viruses including the 
Baculoviridae (baculoviruses) and the Poxviridae (entomopoxviruses) embed virions 
in inclusion bodies [161-163]. Members of the nucleopolyhedroviruses (NPVs), a 
genus in the family Baculoviridae, have rod-shaped, enveloped nucleocapids that 
house a circular, 80-180 kb dsDNA genome and, unlike poxviruses, replicate in the 
nuclei of infected insect cells [164]. Baculoviruses produce two types of infectious 
virions, the budded virus (BV) and the occlusion-derived virus (ODV). Like EVs, 
BVs bud from the plasma membranes of infected cells and are important for systemic 
spread within the insect. ODVs form later during infection in the nuclei of infected 
cells and become embedded in polyhedra [165]. Polyhedra containing ODVs are 
released from the cell by lysis. Following consumption by a susceptible host, the 
polyhedra are dissolved by the strong alkaline pH of the insect midgut to initiate 
primary infection [162].  




primarily composed of a matrix protein is called polyhedrin. Polyhedrin is an 
abundant 30-kDa protein synthesized very late during infection that does not have 
homology to the ATIp [161, 166]. Another viral protein that associates with 
polyhedra is the polyhedron envelope protein (PE). PE forms an envelope coat around 
polyhedra that is thought to provide stability [167] and deletion of the PE gene results 
in the production of fragile polyhedra with structural defects observable by electron 
microscopy [162]. The genes encoding polyhedrin [168] and PE are considered non-
essential because deletion does not affect BV production in tissue culture. The 
mechanism of ODV embedment or occlusion within polyhedra remains to be 
elucidated. However, the Bombyx mori nucleopolyhedrovirus (BmNPV) Bm56 
protein was recently implicated as an occlusion factor [169]. Bm56 is a 15.8-kDa late 
protein that is associated with the NPV nucleocapsid. The deletion of the Bm56 gene 
resulted in the production of aberrant polyhedra lacking embedded ODVs [169]. Like 
the genes required for the formation of polyhedra, the gene encoding Bm56 is 
dispensable in cell culture [169].  
Entomopoxviruses (EPXVs) have a linear, 225 kb dsDNA genome [170]. 
Similar to orthopoxviruses and baculoviruses, EPXV infections result in the 
production of two types of infectious virions: the extracellular virus (EV) and the 
occluded virus (OV). EVs bud from the plasma membrane and are important for 
dissemination within the insect, whereas OVs become embedded within inclusion 
bodies called spheroids that are released from the cell upon lysis [170]. Spheroids 
form in the cytoplasm post-replication and contain mature OVs arranged randomly 




orthopoxvirus MVs and are large (170-250 x 300-400 nm), complex particles 
surrounded by a lipoprotein membrane [171]. OVs comprise at least 40 structural 
proteins although little is known about the location or distribution of those proteins in 
the virus particle [170]. EPXV infections initiate with the ingestion of OV-embedded 
spheroids from which the OVs are liberated in the alkaline conditions of the insect 
midgut. 
Spheroids are ovoid, electron-dense structures consisting of a paracrystalline 
lattice [172] and can vary in size from 5-20 µm [173]. The primary matrix protein of 
spheroids is the 115-kDa late protein, spheroidin, which is the most highly expressed 
entomopoxvirus protein during infection [170, 174, 175]. Spheroidin homologs can 
contain up to 46 cysteine residues, which are thought to be important for assembly 
into inclusions, and the C-terminal 200 amino acids are highly hydrophobic. 
Spheroidin does not share amino acid homology with the ATIp of orthopoxviruses, 
and ATIs are not crystalline structures [175]. The gene encoding spheroidin, sph, was 
found to be dispensable in cell culture despite having high conservation among 
EPXVs [176].  
EPXVs that infect coleopteran (beetles) and lepidopteran (moths and 
butterflies) insects can form another type of inclusion body called spindles, which do 
not contain virions [172]. Spindles are fusiform paracrystalline inclusions composed 
of a single protein called fusolin, which lacks sequence homology to the spheroidin 
and the orthopoxvirus ATIp.  Spindles are found outside of spheroids, but they can 
become occluded in spheroids along with OVs [170, 172]. Although fusolin is 




the protective peritrophic membrane lining the insect gut [177]. 
Baculovirus polyhedra and EPXV spheroids both have fibrils associated with 
them in infected cells. The baculovirus P10 protein interacts with microtubules and 
forms filament-like fibrils early in infection [178, 179]. Later, P10 forms tubular 
structures that lack microtubules and that penetrate the nucleus and associate with the 
surface of the polyhedra. EPXV fibrils are comprised of the filament-associated late 
protein of entomopoxviruses (FALPE)[180]. Unlike P10, FALPE filaments do not 
show an association with host cell microtubules (2). P10 and FALPE share a 
relatively low amino acid identity, however both proteins have a proline-rich stretch 
of amino acids and a basic C-terminal tail [180]. The genes encoding P10 and FALPE 
are both dispensable in tissue culture, and the precise role of fibrils in inclusion 
formation, occlusion, and transmission is not well understood. P10 is thought to assist 
in formation of the PE-envelope [180], because deletion of the p10 gene results in 
fragile polyhedra that resemble those formed in the absence of the PE protein [162]. It 
has been proposed that P10 tubules may confer protection to polyhedra following 
death and decay of the host insect [178]. 
Embedment of insect virions within inclusion bodies mediates efficient 
delivery of infectious virions to the insect midgut and is thought to protect virions 
from heat and UV irradiation during horizontal transmission among emergent 
populations of insects [162]. The biological significance of orthopoxvirus occlusion 
within ATIs is unknown. However, analogous to the inclusion bodies produced by 
insect viruses, inclusion bodies are generally thought to provide stability to MV and 




Chapter 2: Vaccinia virus A26 and A27 proteins form a stable 





Vaccinia virus (VACV), a member of the Poxviridae, undergoes an elaborate 
assembly process involving the sequential formation of morphologically distinct 
infectious virus particles [181]. The mature virions (MVs) are the most abundant 
infectious particles and are released upon cell lysis. The MV consists of: (i) a 
dumbbell-shaped core containing the viral double-stranded DNA genome, structural 
proteins, and enzymes and factors for early gene transcription; (ii) lateral bodies of 
undefined nature that are nestled in the concavities of the core; and (iii) an external 
lipoprotein membrane. Membranes derived from either the trans-Golgi network or 
endosomal cisternae envelop a subset of MV particles to form doubly wrapped 
virions (WVs) [182-184]. WVs traffic along microtubules to the periphery of the cell, 
where the outer membrane fuses with the plasma membrane to release enveloped 
virions (EVs) [185-188]. Many EVs remain associated with the outer surface of the 
plasma membrane and mediate spread to neighboring cells on the tips of actin-
containing microvilli [189, 190]. Some poxviruses (e.g. cowpox, ectromelia, 
raccoonpox, fowlpox, and canarypox but not VACV or variola virus) occlude MVs in 
a proteinaceous body called an A-type inclusion (ATI) that is thought to protect the 
virus particles in harsh environmental conditions [191]. 




approximately 80 polypeptides [192-194]. Although EVs are essentially MVs with an 
outer membrane, there are some differences. Thus, VACV proteins A25 
(VACVWR148) and A26 (VACVWR149) are present in MVs but absent from EVs 
[195]. A25p has a predicted mass of 84 kDa and is a truncated, apparently non-
functional homolog of the cowpox ATI matrix protein [155, 156, 196]. VACV A26 is 
a 58-kDa full-length homolog of the occlusion factor required for incorporating MVs 
into the ATI matrix [197]. Nevertheless, A26p is conserved in orthopoxviruses 
irrespective of their capacity to form ATIs, suggesting an additional role. Ulateo and 
co-workers [195] suggested that A26p acts as a switch to enhance the production of 
MVs at the expense of EVs. Following up on this idea, McKelvey et al. [197] 
suggested that A26p might enhance retrograde transport of MVs. However, the effect 
of deleting the A26 gene on EV production has not been reported. More recently, 
A26p was shown to bind laminin and to function in cell attachment [198].  
In this chapter I show that A26p exists in a complex with three other viral 
proteins: A25p, A27p and A17p. The interaction of A26p and A27p is direct and 
stabilized by a disulfide bond. The interaction of A26p with the A17p transmembrane 
protein is mediated through A27p and this provides the anchor for localization of 
A26p on the surface of MVs. Since A27p is required for EV formation [199], the 
interaction of A26p and A27p provided a plausible mechanism for A26p to negatively 
regulate wrapping. However, EV formation was not enhanced by deletion of A26p in 




2.2 Materials and Methods 
2.2.1 Cells and viruses. 
African green monkey kidney BS-C-1, rabbit kidney epithelial RK-13, and 
human HeLa S3 cell cultures were maintained in minimum essential medium with 
Earle's salts (Quality Biological, Gaithersburg, MD) supplemented with 10% fetal 
bovine serum, 2 mM L-glutamine, 100 units/ml of penicillin, and 100 µg/ml of 
streptomycin. Infections were carried out in medium containing 2.5% fetal bovine 
serum and otherwise supplemented as described above. Recombinant viruses derived 
from the VACV Western reserve (WR) strain were propagated as described 
previously [200].  
2.2.2 Antibodies for Western blotting. 
Rabbit polyclonal antibodies against the following VACV proteins were used: 
A27p [201], A17p [202], and A3p (R. Doms and B. Moss, unpublished data). Anti-
HA (Bethyl Laboratories, Inc., Montgomery, TX) and anti-V5 (Invitrogen, Carlsbad, 
CA) antibodies were conjugated to horseradish peroxidase. 
2.2.3 Recombinant virus and plasmid construction. 
The A27 deletion (vYFP-A4/∆A27 denoted here as v∆A27) and revertant 
viruses (vYFP-A4/∆A27-rev denoted here as v∆A27.Rev) and vA4-YFP used to 
generate v∆A27 were previously described [203, 204]. Both express the yellow 
fluorescent protein fused to the N-terminus of A4 and have A27L deleted from its 
native locus. v∆A27.Rev has a full-length copy of the A27L gene under its native 




generated from a recombinant VACV WR virus that expresses luciferase via a 
synthetic early-late promoter (WRvFire) [205] by replacing the A26L gene with a 
cassette that expresses the enhanced green fluorescent protein. vA26V5 was derived 
from VACV WR by homologous recombination with a PCR product containing the 
A26L gene with a C-terminal V5 epitope tag (GKPIPNPLLGLDST) under the 
control of the A26L promoter and the enhanced green fluorescent protein open 
reading frame (ORF) regulated by the late promoter derived from the A17R gene, and 
A26L downstream flanking sequences. Recombinant viruses expressing enhanced 
green fluorescent protein were clonally purified by four consecutive rounds of plaque 
isolation. Genome modifications were verified by sequencing. 
 pA26V5 was generated by PCR-amplification of V5-tagged A26L from 
vA26V5 genomic DNA using the forward primer 5’-
CTTAACTCTTTTGTTAATTAAAAGTATATTCAAAAAATGAG-3’ and the 
reverse primer 5’-CTACGTAGAATCGAGACCGAGGAGAGGGTTAGGG 
ATAGGCTTACC-3’. The resulting PCR product included the A26L ORF and a 48 
bp upstream region containing the predicted late promoter consisting of an A/T rich 
region and the TAAATG initiator element at the –1 position [206]. pA26∆CV5 
contains the A26L sequence coding for amino acids 1-409 of A26 plus a C-terminally 
appended V5 tag under the control of the A26L promoter sequence as above.  Primers 
5’-CTTAACTCTTTTGTTAATTAAAAGTATATTCAAAAAATGAG-3’ and 5’-
CTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCTTCTT
CTACAGGAAGAAGTTTCGGCCTC-3’ (V5 sequence underlined) were used to 




WR DNA. pA26∆NV5 expresses the C-terminal  220 amino acids of A26 fused to a 
C-terminal  V5  epitope tag.  Forward primer 5’-GAAAAATTTAGCAATG 
ATGCTATACTCGTTTATATTAGAACAAAC-3’ and reverse primer 5’-
CTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACC-3’ 
were used to amplify the C-terminal fragment of A26 from vA26V5 DNA. To add the 
A26 promoter sequence, the above PCR product was used as a template in a reaction 
using the primers 5’-CTTAACTCTTTTGTTAATTAAAAGTATATTCAA 
AAAATGAGTTATATAAATGGAAAAATTTAGCAATGATGCTATACTCG-3’ 
(A26 upstream sequence including the promoter underlined) and 5’-CTACGTAGA 
ATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACC-3’. A plasmid 
including the A27L ORF and the upstream 49 bp shown to be sufficient to drive 
expression of A27 [204] was also generated.  All recombinant PCR products were 
amplified  using Accuprime Pfx (Invitrogen), blunt-end ligated into pCR-BluntII-
TOPO (Invitrogen), and verified by DNA sequencing. 
 The PCR product used to construct pT7.A26V5 was generated using primers 
5’-GGCCGC/TCGAGATGGCGAACATTATAAATTTATGGAACG 
GAATTGTACC-3 and 5’-GGCG/TCGACCTACGTAGAATCGAGACC 
GAGGAGAGG-3’, which introduced N-terminal XhoI and C-terminal SalI restriction 
sites (bold), respectively, for directional cloning into the pTNT vector (Promega, 
Madison, WI) under the control of the T7 promoter. Similarly, the A27L gene was 
amplified with primers 5’- GCCCGGC/TCGAGATGGACGGAACTCTTTT 




TATGGGTACTCATATGGGCGCCGTCCAGTCTG-3’ thereby introducing the 
influenza virus hemagglutinin (HA) epitope tag (YPYDVPDYA) before the stop 
codon to generate pT7.A27HA. 
2.2.4 Transient expression of proteins. 
Six-well plates of BS-C-1 cells were infected at a multiplicity of 5 PFU per 
cell in Opti- MEM reduced serum media (Invitrogen) for 1 h. Following adsorption, 
monolayers were washed twice with Opti-MEM, and 1 µg of each plasmid in 8 µl of 
Lipofectamine 2000 (Invitrogen) in fresh Opti-MEM (Invitrogen) was added. 
Monolayers were harvested after 18-20 h. 
2.2.5 Virus purification. 
 
 MVs were purified from HeLa cell extracts by sedimentation through two 
36% (w/v) sucrose cushions and banding once on a 25 to 40% (w/v) sucrose gradient 
as described previously [207]. For CsCl gradient purification, approximately 6 X 107 
BS-C-1 cells in two T150 flasks were infected with v∆A27 at a multiplicity of 5 PFU 
per cell and then transfected with pA26V5 in the presence or absence of pA27 (1 µg 
each plasmid per 1 X 106 cells). After 24 h, the cells were harvested and subjected to 
two 36% sucrose cushions followed by banding on a 25%-40% sucrose gradient as 
described above. The sucrose gradient purified virus was resuspended in 500 µl of 10 
mM Tris-HCl (pH 9.0) and layered onto a preformed CsCl gradient (1.23 g/ml to 1.29 
g/ml) and centrifuged at 180,000 X g for 4 h at room temperature as described [208]. 
2.2.6 Immunoaffinity purification and Western blot analysis.  




(150 mM NaCl, 50 mM Tris-HCl pH 8.0, 1% NP40) for 30 min on ice. Following 
brief sonication, the extracts were clarified by centrifugation and incubated with 
unconjugated agarose A beads (Invitrogen) for 1 h at 4°C. The extracts were then 
rotated 4-12 h at 4°C with antiserum prior to incubation with pre-washed agarose A 
beads overnight at 4°C. Anti-V5 immunoaffinity purification was carried out per the 
manufacturers instructions using the above lysis buffer. Bound fractions were eluted 
in lithium dodecyl sulfate (LDS) loading buffer (Invitrogen), resolved by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 4-12% 
NuPAGE Bis-Tris gels in NuPAGE MOPS running buffer (Invitrogen), transferred to 
a nitrocellulose membrane and analyzed by Western blotting using rabbit polyclonal 
antiserum and anti-rabbit immunoglobulin G (IgG) conjugated to horse radish 
peroxidase (Pierce, Rockford, IL) consecutively or with anti-V5 antibody and anti-
HA-horse radish peroxidase antibodies as described above. Bound IgG was detected 
using the SuperSignal chemiluminescent substrates (Pierce). For analysis of whole 
cell lysates, cells were collected by centrifugation and resuspended in LDS sample 
buffer (Invitrogen) prior to SDS-PAGE. N-ethylmaleimide (NEM, Sigma) was added 
to cells prior to lysis as previously described [209].  
2.2.7 Biotinylation of purified virions.  
Sucrose gradient-purified virions were rotated with 1 mg/ml of 
sulfosuccinimidyl 2-(biotinamido)-ethyl-1,3-dithiopropionate (EZ-Link sulfo-NHS-
SS-biotin, Pierce) for 30 min at 4°C. Excess biotin was quenched with 50 mM Tris-
HCl, pH 8.0. Virions were pelleted by centrifugation at 20,000 x g for 30 min at 4°C 




proteins, samples were rotated with NutrAvidin agarose beads (Pierce) for 1 h at 4°C. 
The supernatant fraction was removed and the beads were washed five times in cold 
phosphate buffered saline (Quality Biological, Inc.). Biotinylated proteins were then 
eluted using LDS sample buffer plus 50 mM dithiothreitol and analyzed along with 
the unbound fractions by SDS-PAGE and Western blot analysis.  
2.2.8 EV release assay. 
RK-13 and HeLa cells were infected with VACV strain WR or v∆A26 at a 
multiplicity of 0.1 PFU per cell. After 48 h, the supernatant, which contains the EV, 
was removed and clarified using low speed centrifugation. The monolayers, 
containing MV, were washed and lysed by freeze-thawing. Both supernatants and cell 
lysates were titered using BS-C-1 cells and overlaid with medium containing 2.5% 
fetal bovine serum plus 0.5% methylcellulose. After 48 h, plaques were stained with 
crystal violet and counted. To measure adherent EVs, cells were treated with varying 
amounts of trypsin in medium without fetal bovine serum for 45 min at 37˚C [189]. 
Supernatants were removed from monolayers and clarified by low speed 
centrifugation prior to titration as above. 
2.3 Results 
2.3.1 Functional interaction of A26p with A27p.  
During an analysis of proteins in MVs purified from cells infected with the 
A27L deletion mutant vDA27, I noticed that a 60-kDa polypeptide was missing 
(Figure 2-1). The band from the parental virus corresponding to the missing 60-kDa 





Figure 2-1. Absence of A26p in virions lacking A27p. Virions from cells infected 
with v∆A27 and the parental virus vA4-YFP (VACV) were purified by sucrose 
gradient sedimentation, disrupted with LDS and reducing agent, and analyzed by 
SDS-PAGE. Polypeptides were detected by staining them with Coomassie blue. The 
masses of marker proteins (M) are in kDa. The arrowhead labeled A26 points to the 














mass spectrometry. Our initial thought was that A27p was just required for 
incorporation of A26p into MVs. However, extracts of cells infected with v∆A27 had 
very low amounts of A26p compared to the amount from cells infected with the 
parental virus (Figure 2-2A). The deficiency of A26p was specific since the viral A3 
protein and cellular glyceraldehyde-3-phosphate dehydrogenase were present in 
normal amounts. There was no reciprocal effect i.e. deletion of the ORF encoding 
A26p did not cause a decrease in A27 (Figure 2-2A).  
A trivial explanation for the deficiency of A26p would be an unintentional 
mutation of the A26L promoter or ORF during the deletion of the neighboring A27L 
gene. However, DNA sequencing indicated that no such mutation had occurred. 
Furthermore, a normal amount of A26p was detected by Western blotting of extracts 
from cells infected with the revertant virus v∆A27Rev [204], in which a new copy of 
A27L with its natural promoter had been inserted into the VACV thymidine kinase 
locus thereby leaving unaltered the site of the original A27L deletion adjacent to 
A26L. Thus, the synthesis of A27p was necessary for normal amounts of A26p. 
The above data suggested that A27p might be required for the stability of 
A26p. To investigate whether A26p was being actively degraded, cells were infected 
with v∆A27 and the specific proteasome inhibitor MG-132 was added 5 h later. The 
levels of A26p, determined by Western blotting, increased greatly over time in the 
presence of MG-132 (Figure 2-2B), indicating that A26p was being degraded by the 
proteosome in the absence of A27p. In contrast, MG-132 reduced A26p in the 
presence of A27p, presumably due to a general effect (data not shown). I also found 





Figure 2-2. Decreased cytoplasmic A26p in the absence of A27p. (A) Western blot. 
Extracts of cells infected for 24 h with VACV WR (WR), v∆A27.Rev (Rev), v∆A27 
(∆27), or v∆A26 (∆26) were reduced and analyzed by SDS-PAGE, and the proteins 
were identified by Western blotting using antibodies to A26p, A27p, A3p, and 
GAPDH as indicated. (B) Effect of proteasome inhibitor. Cells were infected with 
v∆A27. After 5 h, replicate cultures were treated with 10 µM MG-132 (+) or left 
untreated, and the incubation was continued. At the indicated times, lysates were 
prepared and analyzed by Western blotting with antibodies to A26p and GAPDH. hpi, 











introduction of extra copies of the A26L gene by plasmid transfection and this 
strategy was used in some later experiments. 
2.3.2 A26p and A27p physically interact. 
A physical association between A26p and A2p7 could provide stabilization. 
This idea was supported by our finding of a 90-kDa complex, which reacted with 
antibodies to A26p and A27p, when VACV WR MVs were analyzed by SDS-PAGE 
and Western blotting in the absence of reducing agent (Figure 2-3A). Moreover, only 
faint bands corresponding to the A26p monomer and A27p multimers were detected 
under the latter conditions (Figure 2-3A). After treatment of VACV WR MVs with 
reducing agent, A26p and A27p were resolved as 60- and 14-kDa polypeptides, 
respectively (Figure 2-3A).  Furthermore, when purified v∆A26 virions were 
analyzed, the 90-kDa band was absent and only multimeric forms of A27p were 
detected (Figure 2-3A).  
Taken together, the above data suggested that the 90-kDa band was comprised 
of an A26p-A27p disulfide-bonded complex. Immunoprecipitation experiments were 
carried out to verify the A26p-A27p interaction. To facilitate such experiments, DNA 
encoding a V5 epitope tag was fused to the C-terminus of the A26L ORF and the 
recombinant vA26V5 was clonally isolated. Purified vA26V5 and control VACV WR 
virions were treated with 1% NP-40 to release membrane-associated proteins and 
incubated with V5 antibody that was conjugated to agarose beads. The unbound and 
bound proteins were resolved by SDS-PAGE under non-reducing conditions and 
detected by Western blotting with anti-A27p and -V5 antibodies. When the unbound 








Figure 2-3. A26p and A27p form an SDS-stable complex. (A) Western blot 
analysis of virions. Virions from cells infected with VACV WR (vWR) and v∆A26 
were purified by sucrose gradient sedimentation, dissociated with LDS in the 
presence or absence of reducing agent, and subjected to SDS-PAGE. The blots were 
probed with antibody to A26p and then stripped and reprobed with antibody to A27p. 
The positions of monomeric and oligomeric forms of A27p, monomeric A26p, and 
A26p/A27p complex are indicated. (B) Immunoaffinity purification of A26p/A27p 
complex. Purified virions from cells infected with VACV WR or vA26V5 MV were 




immobilized on protein A beads. Bound (B) and unbound (U) fractions were resolved 
by SDS-PAGE under nonreducing conditions and probed successively with antibody 
to A27p and V5 (left) or with antibody to V5 (right). Pre, eluate from protein A-
agarose beads unconjugated to antibody. (C) Western blot of cell lysates. Cells 
infected with VACV WR or v∆A26 were harvested after 24 h and lysed in the 
presence (+) or absence (-) of 50 mM NEM. The proteins were resolved by SDS-
PAGE under nonreducing conditions, and Western blots were probed with antibody 




























major bands corresponded to the 90-kDa complex and trimeric A27p; no bands were 
detected in the “bound” fraction because of the absence of the V5 tag (Figure 3B). In 
contrast, the A27p antibody reacted with the 90-kDa complex in the bound fraction 
from vA26V5 virions, and only excess trimeric A27p was in the unbound fraction 
(Figure 2-3B). The 90-kDa species was detected in the bound fraction when the blot 
was stripped and re-probed with anti-V5 antibodies confirming that it was an SDS-
stable complex of A26p and A27p (Figure 2-3B). When the reciprocal experiment 
was conducted by incubating NP-40 treated vA26V5 virions with A27p antibody-
conjugated agarose beads, the 90-kDa complex was detected by antibody to A26p 
only in the bound fraction (Figure 2-3B). Taken together, these data indicate that 
A26p was physically associated with A27p in MVs. The Western blotting data 
obtained with VACV WR indicated that the majority of A26p and A27p were present 
as a complex (Figure 2-3A). The presence of substantial amounts of trimeric A27p in 
vA26V5 MVs indicated that the tagged A26V5 was present in lower amounts than 
A27p (Figure 2-3B). The A26p-A27p complex was sometimes detected as a doublet 
suggesting that A26p might be interacting with both A27p trimers and dimers. 
2.3.3 Analysis of the A26p-A27p complex in infected cell lysates. 
Initially, I was perplexed to find that the 90-kDa A26p-A27p complex was not 
detected when infected cell lysates were analyzed by SDS-PAGE and Western 
blotting in the absence of reducing agent; instead monomeric A26p and multimeric 
forms of A27p were resolved (Figure 2-3C). Since the A26p-A27p complex is held 
together by intermolecular disulfide bonds, I considered that these might be disrupted 




group on A27p could displace the disulfide bond between A26p and A27p. An 
established way of preventing disulfide interchange is by adding NEM, which reacts 
with free sulfhydryl groups, prior to cell lysis. When NEM was added in this way, the 
90-kDa complex was visualized by probing Western blots with antibodies to A26p 
and A27p (Figure 2-3C). There was still excess A27p in the cytoplasm, as shown by 
the A27p trimers and dimers, but now there was no free A26p. Therefore, it seems 
likely that the disulfide bond linking A26p and A27p was disrupted by disulfide 
interchange in the absence of NEM. This interchange may be catalyzed by some 
component in the cell extract in the presence of excess A27 since NEM was not 
needed to preserve the covalent A27p-A26p complex isolated from purified virions. 
2.3.4 A26p-A27p complex formation is independent of other viral late proteins. 
A26 and A27 have late promoters and are therefore synthesized following 
viral DNA replication. The following scheme allowed the synthesis of A26p and 
A27p in the absence of DNA replication and other late proteins. Cells were (i) 
untreated or treated with AraC, an inhibitor of DNA replication to prevent late gene 
expression, (ii) infected with vTF7.3, a recombinant VACV that expresses the T7 
RNA polymerase under an early promoter, and (iii) transfected with pT7.A26V5 or 
pT7.A27HA, plasmids that have epitope tagged copies of A26p and A27p, 
respectively, regulated by a T7 promoter. The cells were lysed at 18 h after infection 
and incubated with beads that were conjugated with antibody to the V5 epitope tag on 
A26p. The unbound and bound fractions were treated with reducing agent, resolved 
by SDS-PAGE and analyzed by Western blotting with antibody to the HA tag of 













Figure 2-4. A26p and A27p interact in the absence of other viral late proteins. 
Cells were infected with a recombinant VACV that expresses bacteriophage T7 RNA 
polymerase in the presence (+) or absence (-) of AraC and transfected with plasmids 
encoding epitope-tagged A26p (pT7.A26V5) and A27p (pT7.A27HA) regulated by 
T7 promoters as indicated. After approximately 18 h, the cells were harvested, and 
the lysates were incubated with antibody to V5 attached to beads. The unbound (U) 
and bound (B) fractions were analyzed by SDS-PAGE and Western blotting with 















A27pHA was bound to A26pV5 in the absence or presence of AraC. Furthermore, 
there was no non-specific binding of A27pHA to the V5 antibody in the absence of 
A26pV5 expression (Figure 2-4). The higher expression of A26pV5 and A27pHA in 
the presence of AraC is probably due to the absence of competition by late mRNAs. 
The inhibition of late protein synthesis by AraC was shown by Western blotting with 
antibody to the A3 protein (Figure 2-4).  
2.3.5 A26p is anchored to the MV membrane surface by A27p. 
Since A27p is located on the exterior of the MV membrane, a similar location 
for A26p seemed likely. Indeed, previous studies had shown that the A26p (referred 
to then as 4c or P4c) could be labeled with iodine and released from purified virions 
by treatment with a non-ionic detergent [210, 211]. To confirm by another method 
that A26p was located on the MV surface, I carried out labeling experiments with a 
membrane-impermeable biotinylation reagent. Purified VACV WR virions were 
treated with sulfo-NHS-SS-biotin in the absence or presence of NP-40 detergent, 
which disrupts the MV membrane and exposes core proteins. Samples were incubated 
with NeutrAvidin beads to bind biotinylated proteins and then eluted with buffer 
containing DTT. The unbound and bound fractions were analyzed by SDS-PAGE and 
the Western blot was successively probed with antibody to A26p and A27p. A26p 
was predominantly present in the bound fraction, similar to A27p (Figure 2-5A). The 
A3 core protein was almost entirely in the unbound fraction, suggesting that the MV 
particles were intact and that the biotinylation reagent could not penetrate the viral 
membrane. The failure to biotinylate the A3 protein was not due to intrinsic 












Figure 2-5. A26p is anchored to the MV membrane surface by A27p. (A) 
Biotinylation of A26p and A27p in intact virions. Sucrose gradient-purified virions 
from cells infected with VACV WR were treated with sulfo-NHS-SS-biotin and 
allowed to bind to NeutrAvidin beads. Bound (B) and unbound (U) fractions were 
analyzed by Western blotting with antibodies that recognized A26p, A27p, and A3p. 
As a positive control, purified virions were treated with NP-40 prior to biotinylation. 
(B) Incorporation of A26p into purified virions. Cells were infected with v∆A27 and 
transfected with pA26V5 with or without pA27. After approximately 24 h, the cells 
were harvested and virions were purified by sedimentation through sucrose cushions 
and CsCl gradient sedimentation. Fractions (1 ml) were collected from the top and 














NP-40 and bound to NeutrAvidin beads (Figure 2-5A). 
In our initial experiment (Figure 2-1), the absence of A26p in MVs produced 
in cells infected with v∆A27 could have been due mainly to the instability of A26p. It 
was important, therefore, to determine whether A27p was also required for the 
association of A26p with MVs. As mentioned above, I found that the amount of A26p 
in cells infected with v∆A27 could be increased by introduction of extra copies of the 
A26 gene by transfection. Cells were infected with v∆A27 and co-transfected with 
the plasmid pA26V5, which expresses a V5 epitope-tagged A26p, either alone or 
together with the plasmid pA27, which expresses A27p. Virions were purified from 
the cell lysate by two successive sedimentations through a 36% sucrose cushion 
followed by CsCl gradient centrifugation. Gradient fractions were analyzed by SDS-
PAGE under non-reducing conditions and Western blotting. In the samples from the 
cells transfected with the two plasmids, both A26pV5 and A27p were detected in a 
90-kDa band in fractions 10 and 11 with the A3 core protein, corresponding to the 
expected MV density of ~1.27g/ml (Figure 2-5B). Additional A26pV5 and A27p 
were present in the first several fractions near the top of the gradient. When A27p was 
not expressed, then A26pV5 was present in the upper fractions as a 60-kDa protein 
and was absent from the lower MV fractions containing the A3 core protein (Figure 
2-5B). Thus, these data indicate that the association of A26p in the MV membrane is 
dependent upon A27p. 
2.3.6 The A26-A27 complex is associated with A17 and A25. 
Affinity purification was carried out to determine whether additional proteins 




interested in A17p, since the latter protein anchors A27p to the viral membrane [199]. 
Cells were infected with vA26V5 or VACV WR and lysates were incubated with 
antibody to V5 coupled to beads. The bound proteins were eluted and visualized by 
staining after SDS-PAGE (Figure 2-6). Several bands were specific for cells infected 
with vA26V5, whereas a few others were non-specific. The specific bands were 
excised and A25p, A26p, A17p and A27p were identified. Based on the intensity of 
the stain, A25p and A17p appeared to be present in lesser amounts than A26p and 
A27p (Figure 2-6). However, this may reflect the stability of the interactions rather 
than the stoichiometry of the complex. Proteins corresponding to other faint bands 
could not be identified by mass spectroscopy analysis. 
Immunoprecipitation and Western blotting confirmed the association of A17p 
with the A26p-A27p complex in virions. MVs purifed from cells infected with 
vA26V5 were treated with NP-40 and then incubated with beads that were conjugated 
with antibody to A17p. A26pV5 was detected by Western blotting of proteins that 
were immunopurified with anti-A17p antibody (Figure 2-7A).  
2.3.7 Association of A26p with A17p is mediated by A27p. 
 
Since A27p is known to interact with A17p [199], the association of the latter 
with A26p could be indirect. Alternatively, A26p might also bind A17p directly. To 
investigate these alternatives, cells were infected with v∆A27 and transfected with 
combinations of plasmids expressing bacteriophage T7 RNA polymerase from a 
VACV promoter, and A26V5 and A27HA from T7 promoters. When all three 
plasmids were transfected, beads coupled to V5 antibody pulled down A26pV5, 






Figure 2-6. Association of A17p, A25p, and A27p with A26p determined by mass 
spectrometry. Sucrose gradient-purified virions from cells infected with vA26V5 or 
VACV WR were treated with NP-40 and then bound to V5-specific antibody bound 
to beads. The bound proteins were resolved by SDS-PAGE and stained with 
Coomassie blue. The bands were excised, digested with trypsin, and analyzed by 











Figure 2-7. Association of A26p with A17p was dependent on A27p. (A) 
Immunopurification of A26 with immobilized A17. MVs purified from cells infected 
with vA26V5 were treated with NP-40 and incubated with antibody to A17 attached 
to protein A beads. Unbound (U) and bound (B) fractions were subjected to SDS-
PAGE and Western blotting with antibody to the V5 epitope. (B) Immunoaffinity 
purification of A17 and A27 with A26. Cells were infected with v∆A27 and 
transfected with a plasmid expressing the T7 polymerase (pTF7.3) and plasmids 
expressing A26V5 (pT7.A26V5) and/or A27HA (pT7.A27HA) under the control of 
the T7 promoter. After approximately 24 h, the cells were harvested, lysed with NP- 
40, and incubated with antibody to V5 attached to beads. Proteins in the unbound and 
bound fractions were resolved by SDS-PAGE and analyzed by Western blotting with 




was omitted, only A26pV5 was captured. Thus, A27p was required for the interaction 
of A26p with A17p. 
2.3.8 The C-terminus of A26p mediates interactions with A27p. 
The C-terminal region of A26p, from amino acids 441 to 472, shares a 44% 
amino acid identity with the A27p C-terminal, alpha helical “anchoring domain” 
through which A27p mediates interactions with A17p and the MV particle [212]. 
Two plasmids were constructed: pA26∆NV5 expressed the C-terminal 270-500 
amino acids and included the region of homology with A27p; whereas, pA26∆CV5 
coded for amino acids 1-409, excluding the region of homology to A27p (Figure 2-
8A). Cells were infected with v∆A26 and transfected with either empty plasmid or 
plasmids expressing full length A26V5 or the deletion mutants. After 18 h, the cells 
were lysed with 1% NP40 and the soluble extract was incubated with anti-V5 
conjugated beads. The unbound and bound fractions were resolved by SDS-PAGE 
under reducing conditions and probed with antibodies against A26p, A27p, and A17p. 
Full-length A26p and the C-terminal 220 amino acid fragment from pA26∆NV5 
pulled down A27p and A17p (Figure 2-8B). Neither A27p nor A17p, however, were 
present in the bound fractions from cells expressing the C-terminal deleted form of 
A26p from pA26∆CV5 (Figure 2-8B). The region from amino acids 270 to 500 
contains three cysteines, at least one of which may be involved in the disulfide bond 
with A27p.  
2.3.9 Deletion of A26 does not increase EV formation. 






Figure 2-8. The C terminus of A26p interacts with A27p. (A) Schematic drawings of 
truncated A26 ORFs. pA26V5, pA26∆CV5, and pA26∆NV5 show the lengths of V5 
epitope-tagged A26 plasmid inserts. Black shading, A26p sequence; dark gray, region 
of homology with A27p; light gray, V5 epitope tag. A26 amino acid residues are 
numbered. (B) Western blots of immunoaffinity-purified A26-associated proteins. 
Cells were infected with v∆A26 and mock transfected or transfected with pA26V5, 
pA26∆CV5, or pA26∆NV5. Lysates were incubated with antibody to V5 coupled to 
beads, and the unbound and bound fractions were analyzed by SDS-PAGE and 
Western blotting with antibody to V5, A17p, and A27p. The positions and masses in 







that A26p negatively regulates wrapping [195]. Our finding that A26p interacted with 
A27p, which is required for wrapping, could have provided a mechanism for such a 
role. If this hypothesis were correct, then deletion of the A26L ORF should increase 
the amount of EVs. RK-13 and HeLa cells were infected with either v∆A26 or VACV 
WR and the cells and media were harvested separately after 48 h. The deletion of the 
A26L did not increase the amount of EV either released naturally into the medium 
(Figure 2-9A) or liberated from the surface of the cell with trypsin (Figure 2-9B). 
Furthermore, there was no discernible difference in plaque size or comet formation 
due to release of EVs in RK-13 cells infected with v∆A26 as compared to wild-type 
virus (not shown). 
2.4 Discussion 
The present study was initiated following our serendipitous observation that 
A26 was missing from MVs formed by an A27L deletion mutant. Further studies 
indicated that A27 was required for the stability of A26 as well as for its 
incorporation into MVs. The relationship between A26 and A27 was explained by the 
finding that the two proteins formed an SDS-stable complex in the absence of 
reducing agent. The complex migrated as a band of about 90-kDa, likely consisting of 
A26 (58-kDa) disulfide-bonded to A27 (12.6-kDa) trimers or dimers. Moreover, 
nearly all of the A26 and A27 in wild type MVs were in the complex. It was 
surprising, therefore, that this complex was not generally recognized during analysis 
of virion proteins, though it likely corresponds to the heterodimer of 54- and 16-kDa 
polypeptides described by Ichihashi [213]. I had trouble detecting the A26-A27 




















Figure 2-9. Intra- and extracellular virus production. (A) RK-13 and HeLa cells 
were infected with VACV WR or v∆A26 at a multiplicity of infection of 0.1 PFU per 
cell. After 48 h, the media were collected and the intra- and extracellular virus titers 
were determined. (B) The indicated concentrations of trypsin were used to release 
EVs from the surfaces of cells infected with VACV WR and ∆A26 for 24 h. Virus 









prevent disulfide interchange, perhaps providing an explanation for failure of others 
to observe the complex. Further studies indicated that no additional viral late proteins 
were required for the interaction of A26 and A27. Co-immunoprecipitation 
experiments indicated that the C-terminal segment of A26 interacted with A27. 
Interestingly, part of that region shares sequence homology with A27. These data are 
consistent with an observation that the C-terminal 75 amino acids of A26 are required 
for anchoring the latter protein to the MV particle, although an interaction with A27 
was not proposed at the time [198].  
The A26-A27 complex also associated non-covalently with the A17 and A25 
proteins. A17, a transmembrane protein, had previously been shown to interact with 
A27 [199], and our study indicated that the association of A26 with A17 was indirect 
and dependent on A27. The inability of A26 to interact directly with A17 (or any 
other integral membrane protein) explains why A27 is needed for incorporation of 
A26 into MVs. Biotinylation studies confirmed that A26 and A27 were exposed on 
the surface of the MV-membrane  
The finding of a multiprotein A17, A25, A26 and A27 complex has interesting 
implications. Previous studies have shown that the formation of the ATI is dependent 
on a full-length ortholog of the truncated A25 protein and that A26 is needed for the 
embedding of virions within them [197]. The role of A26 in this process has not been 
elucidated, although a role in retrograde transport on microtubules was suggested. 
The interaction of A26 with A25, shown here, suggests a direct role of A26 in 
attaching virions to the ATI. It is thought that the inclusions protect virions in a 




reduction in EVs, which are important for cell-to-cell spread, appears to be a 
consequence of virion occlusion since this results in smaller size plaques [214, 215]. 
Ulateo and coworkers [195] suggested a related role for A26 in orthopoxviruses that 
do not make ATIs. Primarily because A26 was found in MVs but not EVs, they 
suggested that A26 might negatively regulate wrapping. Our finding that A26 
interacts with A27, which is required for MV-wrapping [216], made the hypothesis 
that A26 modulates EV formation even more attractive. Nevertheless, I did not 
discern a change in the ratio of EVs to MVs when the A26L ORF was deleted. It 
remains possible, however, that the number of MVs lacking A26 were not limiting for 
wrapping in the two cell lines that were tested but that the situation would be different 
with other cells, other VACV strains or other incubation conditions. I did find a 
reduction in EV production when A26 was over expressed, but this was correlated 
with a reduction in expression of other viral proteins including A27 and was therefore 
difficult to interpret (our unpublished data).  
A26 appears to have a role in cell attachment as it was shown that A26 binds 
laminin, an extracellular matrix protein, and soluble laminin partially blocks MV 
binding to cells [198]. Chiu et al. [198] reported that virions lacking A26 are still 
infectious and I confirmed this more directly with an A26L deletion mutant. 
Retention of infectivity was not surprising since VACV encodes other proteins that 
mediate cell attachment by binding glycosaminoglycans [217, 218]. Since A27 is one 
of the three glycosaminoglycan-binding proteins, there could be functional 




Chapter 3: Congregation of Orthopoxvirus Virions in Cytoplasmic 
A-type Inclusions is Mediated by Interactions of a Bridging Protein 
(A26p) with a Matrix Protein (ATIp) and a Virion Membrane-
Associated Protein (A27p) 
 
3.1 Introduction 
 The orthopoxviruses, which include the best characterized and medically most 
significant members of the poxvirus family, produce two major types of infectious 
particles known as mature virions (MVs) and enveloped virions [181]. MVs are 
assembled at cytoplasmic, juxtanuclear viral factories and consist of a core containing 
viral double-stranded genomic DNA, enzymes and factors necessary for early gene 
transcription, and structural proteins surrounded by a lipoprotein membrane. A 
population of MVs traffics along microtubules and acquires two additional 
membranes derived from trans-Golgi or endosomal cisternae to form wrapped 
virions. Wrapped virions traverse the cell along microtubules to the plasma 
membrane where the outer viral membrane fuses with the plasma membrane to allow 
exit of enveloped virions. However, the majority of MVs remain in the cytoplasm 
until cell lysis. The MVs of some orthopoxviruses, e.g. cowpox virus (CPXV), 
ectromelia virus and raccoonpox virus have an additional fate: they become 
embedded in dense, proteinaceous bodies called A-type inclusions (ATIs) that are 
distinguished from virus factories [146-148]. Orthopoxviruses that do not form A-
type inclusions include vaccinia virus (VACV), the prototype of the poxvirus family, 
variola virus, the causative agent of smallpox, and monkeypox virus, an emerging 




avipoxviruses and entomopoxviruses (3) and may protect virions from harsh 
environmental conditions during transmission between hosts.  
 ATIs form subsequent to viral DNA replication and the matrix consists of a 
single known viral late protein, the ATIp [151]. The ATIp is an abundant, high 
molecular weight (160 kDa in CPXV), hydrophobic protein that contains 14 repeats 
of about 30 amino acids each [151, 154]. Orthopoxviruses that do not form inclusion 
bodies have mutated ATI genes. An ATIp homolog encoded by the A25L gene 
(VACVWR148) of the Western Reserve (WR) strain of VACV contains a deletion of 
two adenylate residues resulting in synthesis of a C-terminally truncated, 94-kDa 
protein [151, 155, 156]. This A25 protein (A25p) contains the N-terminal half of 
ATIp including the first four ATIp repeats and six amino acids of the fifth repeat. The 
embedding of MVs in inclusions requires a protein encoded by homologs of the 
A26L gene, which is mutated in some orthopoxvirus strains (27, 42). Although 
VACV does not form inclusion bodies, the VACV A26L gene (VACVWR149) is 
intact, and the VACV A26 protein (A26p) can complement the defective A26p 
homolog in the Brighton red (BR) strain of CPXV (CPXV-BR) [160]. Whether 
VACV is missing other proteins needed for inclusion formation and occlusion was 
not known prior to the present study. 
 The mechanism by which A26p mediates occlusion had not been elucidated, 
although a role in retrograde transport of MVs was suggested [160]. Recently, A26p 
was shown to be anchored to the MV membrane through disulfide bonding with the 
A27 protein (A27p) [219, 220], which is in turn tethered to the MV membrane 




finding that A26p also interacts with A25p (16), suggested that it might similarly 
interact with the intact ATIp, thereby localizing MVs in inclusion bodies. To 
investigate the role of A26p in mediating occlusion, I constructed recombinant 
VACV expressing the CPXV-BR ATIp in place of the truncated VACV-WR A25p. 
Remarkably, this single alteration allowed VACV to produce typical inclusions 
containing MVs. Occlusion of MVs by recombinant VACV was dependent on both 
A26p and A27p, even though inclusions formed without either of these proteins. 
A26p localized with inclusions in the absence of A27p or MV production, consistent 
with a direct interaction with ATIp. Separate domains of the ATIp were shown to be 
required for inclusion formation and association with A26p. Taken together, the data 
present a working model of occlusion in which A26p serves as a bridge between 
A27p on MVs and ATIp in inclusion bodies.  
3.2 Materials and methods 
3.2.1 Cells and viruses. 
African green monkey kidney BS-C-1 and human HeLa cell cultures were 
maintained in minimum essential medium with Earle's salts (Quality Biological, 
Gaithersburg, MD) and 10% fetal bovine serum (FBS). The medium was further 
supplemented with 2 mM L-glutamine, 100 units/ml of penicillin, and 100 µg/ml of 
streptomycin. Cells were infected with viruses in medium containing 2.5% FBS and 
supplements listed above. Recombinant viruses were derived from the VACV-WR 





3.2.2 Plasmid and recombinant virus construction. 
 The following recombinant viruses were constructed by standard methods: (i) 
vA25HA.A26V5, which expresses an influenza hemagglutinin (HA) epitope-tagged 
VACV A25p and a V5-tagged VACV A26p; (ii) vATIHA.A26V5, which encodes an 
HA-tagged CPXV ATIp and a V5-tagged A26p; and (iii) vATIHA.∆A26, which has 
A26L deleted and expresses an HA-tagged ATIp. In the first step, the VACV WR 
A25L gene was replaced by the enhanced green fluorescent protein (GFP) gene to 
generate v∆A25.GFP. Plasmids were then constructed to insert the cassettes of 
interest into the GFP locus of v∆A25.GFP. Briefly, the plasmids used to make 
vA25HA.A26V5 and vATIHA.A26V5 contained the left flanking region of the A25L 
ORF with a PacI site introduced immediately downstream of the A25L stop codon. 
The right flanking region was amplified with DNA encoding a V5 tag introduced into 
to the C-terminal coding region of A26L and a SalI site immediately downstream of 
A26L and upstream of the A25L ORF. The two flanks were joined by overlap PCR 
using Accuprime Pfx (Invitrogen, Carlsbad, CA) and blunt-end ligated into pCR-
BluntII-TOPO (Invitrogen) to generate the pFLANKS plasmid. pFLANKS∆A26 was 
constructed similarly to make vATIHA.∆A26 except that the right flanking region 
was amplified from the A27L gene which is immediately upstream of the A26L ORF. 
The VACV-WR A25L and CPXV-BR ATI genes and native promoters were 
amplified with forward and reverse primers introducing an upstream SalI site and 
DNA sequences coding for the HA tag with a downstream PacI site, respectively. 
The PCR products were subcloned into pCR-BluntII-TOPO and the resulting 




excised from pA25HA and pATIHA using SalI and PacI for ligation with linearized 
pFLANKS and pFLANKS∆A26 to generate pFLANKS.A25HA and 
pFLANKS.ATIHA and pFLANKS∆A26.ATIHA, respectively. v∆A25.GFP-infected 
cells were transfected with linearized pFLANKS.A25HA and pFLANKS.ATIHA and 
pFLANKS∆A26.ATIHA using Lipofectamine 2000 (Invitrogen) per the 
manufacturer’s instructions. Control viruses with an A26L-A25L double deletion 
(v∆A25.∆A26), an HA-fused A25L with a deleted A26L (vA25HA.∆A26), and a 
deleted A25L with a V5-fused A26L (v∆A25.A26V5) were generated similarly as 
above. Recombinant viruses were clonally purified by consecutive rounds of white-
plaque selection [221]. The A4:YFP fusion was introduced as previously described 
[108].  
 The A27L deletion (v∆A27) virus containing the yellow fluorescent protein 
(YFP) fused to the N-terminus of A4p was described previously [108]. v∆A27 forms 
small plaques, and v∆A26.A4:YFP was generated from v∆A27 by inserting a cassette 
that deleted A26L but restored A27L at the A27L-A26L locus and selecting for large 
plaques. 
The ATI deletion mutants were amplified from the pATIHA plasmid and 
cloned into the pTOPO vector. N-terminal deletion mutants were amplified using 
forward primers containing the CPXV-BR ATI promoter and an introduced start 
codon adjacent to at least the first ten 5’ nucleotides of the target sequence and a 
reverse primer to the HA tag. C-terminal mutants were amplified using a forward 
primer complementary to the ATI promoter and a reverse primer overlapping the HA 




pATIFLAG was generated by amplifying the ATI gene with a reverse primer coding 
for the FLAG epitope tag with the amino acid sequence DYKDDDDK. pA27HA, 
pA26V5, pA26∆NV5, and pA26∆CV5 were described previously [219]. 
3.2.3 Antibodies. 
Mouse monoclonal antibodies (MAbs) and rabbit polyclonal antibodies 
(PAbs) against the HA (YPYDVPDYA) and mouse MAbs against the V5 
(GKPIPNPLLGLDST) epitope tags used for Western blotting were obtained from 
Covance (Princeton, NJ). Rabbit PAbs against A26p [219] and A3p (R. Doms and B. 
Moss, unpublished data) were also used for Western blotting. Immunofluorescence 
staining of the HA-tagged A25p, ATIp, and A27p was carried out using either rat 
MAbs (clone 3F10) from Roche Applied Sciences (Indianapolis, IN) or mouse MAbs 
or rabbit PAbs from Covance at 1:250 dilutions. Mouse MAbs and rabbit PAbs to V5 
as well as mouse MAbs to FLAG were obtained from Sigma-Aldrich (St. Louis, 
MO). Mouse MAb to V5 from Abcam (Cambridge, MA) was also used. Alexa-
conjugated anti-rat, anti-rabbit, and anti-mouse immunoglobulin G (IgG) were used at 
1:250 (Invitrogen). 
3.2.4 Immunoaffinity purification. 
As described previously [219], cells were solubilized in lysis buffer (150 mM 
NaCl, 50 mM Tris-HCl pH 8.0, 1% NP40) by rotating at 4°C for 30 min. The extracts 
were cleared and incubated with unconjugated agarose A beads prior to incubation 
with mouse anti-V5 immunoaffinity beads (Sigma). Bound proteins were eluted by 




the addition of reducing agent (Invitrogen), samples were resolved by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 4-12% NuPAGE Bis-
Tris gels in NuPAGE MOPS running buffer (Invitrogen). 
3.2.5 Western blotting. 
Whole cell extracts for Western blotting were prepared by incubating virus-
infected cells in 10 mM Tris-HCl, pH 7.4, 10 mM CaCl2, 10 mM NaCl with 8 μg/ml 
micrococcal nuclease and 0.5% NP-40 for 30 min on ice followed by brief sonication 
[28]. LDS and reducing agent were added, and the samples were boiled prior to 
resolution by SDS-PAGE as described above. Proteins were transferred 
electrophoretically to a nitrocellulose membrane and detected using antibodies as 
described above and anti-rabbit or anti-mouse IgG conjugated to horse radish 
peroxidase (Pierce, Rockford, IL), which was developed using SuperSignal 
chemiluminescent substrates (Pierce).   
3.2.7 Infection and transfection. 
Dishes with 24-wells containing cover slips seeded with approximately 2.5 X 
105 HeLa cells for confocal microscopy were infected at a multiplicity of infection of 
0.1 PFU per cell in Opti-MEM (Invitrogen). After 1 h, cells were washed and 
transfected with 200 ng of plasmid using Lipofectamine 2000 (Invitrogen) per the 







3.2.8 Confocal microscopy. 
HeLa cells were washed three times in room temperature Dulbecco’s 
phosphate buffered saline (PBS) without Ca2+ and Mg2+ prior to fixing for 10 min in 
4% paraformaldehyde in PBS. Cells were washed 4 times and permeabilized with 
0.2% triton X for 7 min. Four 5 min washes in PBS were used to insure the removal 
of triton X. Prior to staining, cells were blocked in 10% FBS/PBS for 1 h. Primary 
staining was carried out at room temperature for 1 h in 10% FBS/PBS. Four 5 min 
washes in PBS were used to remove any unbound antibody, and secondary staining 
was carried out in 10% FBS/PBS for 45 min. Cells were subjected to four 5 min PBS 
washes, and coverslips were mounted onto slides using ProLong Gold with or without 
4',6'-diamidino-2-phenylindole (DAPI) mounting medium (Invitrogen). A Leica SP2 
inverted four-channel microscope was used for imaging. Select images were 
deconvolved using Huygens Essential version 3.5.0, 64 bit (Scientific Volume 
Imaging, Hilversum, Netherlands) and brightness and contrast were adjusted using 
either Imaris Bitplane Scientific Software version 6.4.2 (Saint Paul, MN) or Adobe 
Photoshop CS3 (Adobe Systems, San Jose, CA, USA). 
3.2.9 Electron microscopy. 
BS-C-1 cells in 60-mm-diameter dishes were infected with recombinant 
viruses at a multiplicity of infection of 10 PFU per cell. Cells were fixed with 2% 
glutaraldehyde at 22 h post infection and embedded in EmBed-182 resin (Electron 
Microscopy Sciences, Hatfield, PA). Samples were viewed with a FEI Tecnai Spirit 






3.3.1 Restoration of full-length ATIp allows inclusion body formation in cells 
infected with recombinant VACV. 
I was interested in determining whether replacement of the disrupted ATI 
gene of VACV with the full-length CPXV homolog would be sufficient to support 
inclusion body formation and occlusion for two main reasons: a negative result would 
suggest the need for additional CPXV genes, which I would then try to identify; a 
positive result would allow us to study occlusion in the VACV background, which is 
better characterized than CPXV. The region of CPXV-BR encoding the full length 
1,284 amino acid ATIp (ORF 158) and the disrupted A26p homolog (ORFs 159, 160 
and 161) is shown in Fig. 1A. In contrast, four smaller ORFs (145, 146, 147 and 148) 
comprise the disrupted ATIp homolog of VACV-WR whereas ORF 149 encoding 
A26p is intact (Figure 3-1A). VACV ORF 148, encoding the expressed 725-amino 
acid A25p, has a late promoter whereas ORFs 145, 146 and 147 are probably not 
expressed as they lack recognizable promoters. To avoid potential complications due 
to recombination during the reconstruction of the VACV genome, ORFs 145-148 
were deleted from the VACV genome prior to insertion of the complete CPXV-BR 
ATI gene with a C-terminal HA epitope tag and the native ATI promoter. The VACV 
ORF encoding A26p was replaced with a V5-tagged version or deleted (Figure 3-
1A.). Another recombinant virus was constructed encoding an HA-tagged VACV 
A25p and a V5-tagged VACV A26p to be used as a control that does not form 
inclusion bodies. In each case, the YFP ORF was fused to the ORF encoding the 
VACV core protein A4p (A4YFP) to visualize MV by confocal microscopy. The 







Figure 3-1. Construction of recombinant VACV expressing ATIp. (A) Schematic 
drawings of the ATI and neighboring loci in CPXV-BR, VACV-WR, and 
recombinant VACV-WR. Recombinant viruses were made by replacing the truncated 
A25L gene (VACVWR148) with the full-length ATI gene (CPXVBR158) containing 
a C-terminal HA-epitope tag or an A25L gene containing a C-terminal HA-epitope 
tag (white diamond). The VACV A26L gene (VACVWR149) was either deleted or 
given a C-terminal V5-epitope tag (black diamond). The ATI and A25L genes are 
flanked by introduced SalI and PacI sites. Additional control viruses with deletions of 
A25L or A26L are not shown. (B) Western blot confirming expression of ATIp or 
A25p from recombinant viruses. Extracts of HeLa cells infected with vA25-A26- 
(lane 1), vA25+A26- (lane 2), vATI+A26- (lane 3), vA25-A26+ (lane 4), vA25+A26+ 
(lane 5), vATI+A26+ (lane 6) were resolved by SDS-PAGE under reducing 
conditions. ATIp and A25p were identified using anti-HA antibodies and A26p was 
detected with anti-A26p antibodies. Precursor and processed forms of VACV late 
protein A3p were detected with antibody as a loading control. The sizes in kDa and 





[108]. The recombinant viruses formed normal looking plaques (not shown) 
indicating that the genome alterations had little or no effect on replication. Because 
use of the full descriptive names of the recombinant viruses is cumbersome, I will 
generally omit reference to the epitope tags and YFP fusion and simply refer to 
recombinant viruses with intact ATIHA as ATI+, A25HA as A25+, and A26V5 as 
A26+ as indicated in Table 1. Viruses with a deletion of A25 or A26 will be referred 
to as A25- or A26- (Table 3-1).  
Whole cell lysates from cells infected with vATI+A26+ and vA25+A26+ or 
with control viruses missing one or two genes: vATI+A26-, vA25+A26-, vA25-A26+, 
and vA25-A26- were analyzed by Western blotting to determine if the CPXV-BR 
ATIp was expressed in the VACV background. Proteins were resolved by SDS-
PAGE under reducing conditions, and anti-HA antibodies revealed bands migrating 
to positions corresponding to the expected masses of approximately 94 and 160 kDa 
for A25p and ATIp, respectively (Figure 3-1B). Slower migrating bands, which 
presumably represent incompletely dissociated oligomeric forms of ATIp, were also 
detected in samples from vATI+A26+ and vATI+A26--infected cells. In contrast, SDS-
resistant oligomeric forms of A25p were not detected. Bands representing lower 
molecular weight processed species of both A25p and A26p were also detected by 
Western blotting (shown later). A26p was resolved as a 60-kDa protein detected by 
Western blotting using anti-A26p antibodies in lysates from cells infected with vA25-
A26+, vA25+A26+, vATI+A26+ but not vA25-A26-, vA25+A26-, and vATI+A26- 
(Fig.1B). Antibody to the A3p VACV core protein was used as a loading control. 





Table 1. Abbreviated nomenclature for recombinant viruses. 
 
Full Descriptive name      Abbreviated name 
vA25HA.A26V5.A4YFP             vA25+A26+            
vATIHA.A26V5.A4YFP             vATI+A26+ 
vA25HA.ΔA26.A4YFP             vA25+A26- 
vATIHA.ΔA26.A4YFP             vATI+A26- 
vΔA25.A26V5.A4YFP             vA25-A26+ 
vΔA25.ΔA26.A4YFP             vA25-A26- 






and vATI+A26-, I investigated the formation of inclusion bodies by confocal 
microscopy. HeLa cells were infected with vA25+A26+, vATI+A26+, or vATI+A26- 
and fixed 18 h later. The cell nucleus and DNA factories, which were moderately 
dispersed at this late time, were visualized by DAPI staining. Anti-HA staining was 
used to detect A25p or ATIp, and anti-V5 staining was used for A26p localization. In 
cells infected with vA25+A26+, the A4:YFP core protein partially co-localized with 
virus factories and with punctate structures presumably representing virus particles 
distributed throughout the cytoplasm (Figure 3-2A, row 1). A26p co-localized with 
A4p:YFP, whereas the abundant A25p was diffusely distributed (Figure 3-2A, row 1). 
Western blotting and immunoprecipitation experiments carried out using purified 
vA25+A26+-virions showed that the HA tag did not disrupt either the virion 
association of A25 or the A26-A25 interaction (data not shown). 
Optical sections of cells infected with vATI+A26+ and stained with antibodies 
that recognized the HA tag on ATIp revealed distinct ring-like structures (Figure 3-
2A, row 2) in contrast to the diffuse staining of A25p (Figure 3-2A, row 1). Similar 
peripheral staining patterns of inclusion bodies by anti-ATIp antibodies were seen in 
previous studies in which the authors suggested that inclusion bodies are 
impermeable to the antibody-conjugate [151]. MV particles, detected by the YFP 
fluorescence, were associated with ATI as early as 8 h (not shown) and encrusted and 
filled the inclusions by 18 h (Figure 3-2A, row 2). Anti-V5 staining showed that 
A26p was associated with the inclusions and non-occluded MVs (Figure 3-2A). The 






Figure 3-2. Recombinant VACV inclusion body formation and occlusion. (A) 
Confocal microscopic images of HeLa cells infected with vA25+A26+ (first row), 
vATI+A26+ (second row), and vATI+A26- (third row) were fixed, permeabilized, and 
stained at 18 h after infection. DAPI used to stain DNA in the nucleus and viral 
factories (blue) is shown in the merge. Rabbit anti-HA antibodies followed by Alexa 
647-conjugated anti-rabbit IgG were used to stain A25p and ATIp (cyan). MV 
particles were visualized using YFP fluorescence (green). Mouse anti-V5 antibodies 
followed by Alexa 594-conjugated anti-mouse IgG was used to stain A26p (red). 
Inclusion bodies are denoted by arrowheads. Scale bars, 10 µm. (B) 3D 
reconstruction of cell infected with vATI+A26+ at 18 h post infection and stained as 
above. ATIpHA (red) staining shows inclusion bodies are quasi-spherical and 




undetectable in their interior, presumably due to antibody inaccessibility. Three-
dimensional reconstructions (Imaris Bitplane Scientfic Software, Saint Paul, MN) of 
optical sections of vATI+A26+-infected cells showed the peripherally stained 
inclusions as quasi-spherical bodies  studded or packed with A4-YFP-fluorescing MV 
particles (Fig. 2B). 
In cells infected with vATI+A26-, inclusion bodies formed but MV particles 
did not associate with them (Fig. 2A, row 3), confirming the requirement for A26p as 
observed previously for CPXV mutants [152, 157, 160, 222]. These experiments 
indicated that expression of the full length ATIp conferred upon VACV the ability to 
form inclusions and to occlude MVs. Thus, VACV-WR encodes all viral proteins 
needed for occlusion except for the full-length ATIp. 
3.3.2 Fine structure of VACV inclusion bodies. 
Transmission electron microscopy was used to visualize inclusion bodies and 
associated MVs at higher magnification. Sections were prepared from BS-C-1 cells 
infected with either vATI+A26+or vATI+A26- at 22 h post infection. In cells infected 
with vATI+A26+, characteristic large, electron-dense granular inclusion bodies were 
seen and MVs were embedded throughout the proteinaceous matrices of most (Figure 
3-3A). Other forms of VACV including immature and wrapped virions were not 
closely associated with inclusion bodies. Inclusion bodies also formed in cells 







Figure 3-3. Transmission electron microscopy of inclusion bodies. BS-C-1 cells 
infected with 10 PFU of vATI+A26+ (panel A) or vATI+A26- (panel B) per cell were 
fixed at 24 h after infection. Electron microscopic images of thin sections are shown. 

















3.3.3 Construction and expression of ATIp truncation mutants. 
To distinguish the domains of ATIp necessary for formation of inclusion 
bodies and for occlusion of MVs, a panel of plasmids expressing N-terminal or C-
terminal truncated ATIps was constructed. Each mutant ATIp had a C-terminal HA 
epitope tag to allow detection. Mutants ΔN1-100, ΔN1-300, and ΔN1-412 have N-
terminal deletions of 100-, 300-, and 412-amino acids, respectively (Figure 3-4A). 
Mutants ΔNcc1, ΔNcc1/2, and ΔNcc1/2/3 have more extensive N-terminal deletions 
extending through the first, second, and third coil-coil domains, respectively (Fig. 
4A). The entire N-terminal half of the protein including repeats 1- 4 was deleted in 
the mutant ΔNRep1-4’. A set of C-terminal truncations was made by incrementally 
deleting repeats up to the amino acid sequences included in A25p (Figure 3-4A). 
To examine expression of the mutant proteins, BS-C-1 cells infected with 
vA25-A26+ were transfected with plasmids encoding the mutant ATIps regulated by 
the natural ATIp promoter. Proteins in whole cell lysates were resolved by SDS-
PAGE under reducing conditions and transferred to nitrocellulose membranes for 
Western blotting with anti-HA antibodies. Prominent bands migrated to positions 
corresponding to the reported 160 kDa for ATIp and 94 kDa for VACV A25p as well 
as the predicted masses of the mutant proteins (Figure 3-4B). Multiple bands were 
detected for ATIp, A25p, and ATIp mutants presumably representing larger 































Figure 3-4. Construction and expression of truncated ATIps. (A) Schematic of 
ATIp and N- and C-terminal truncated versions with C-terminal HA tag. The 14 ATIp 
repeats (black boxes) are numbered. Gray bars represent predicted coil-coil domains. 
ΔN followed by numbers indicate the amino acids deleted from the N-terminus; ΔNcc 
followed by numbers indicate deletion of coil-coil domains from the N-terminus; 
ΔNRep followed by a numbers indicate the deletion of repeat sequences from the N-
terminus; ΔCRep followed by numbers indicate deletion of repeat sequences from the 
C-terminus; ΔC followed by numbers indicate amino acids deleted from C-terminus. 
(B) Detection of HA-tagged ATIp and truncated forms by Western blotting. Proteins 
from BS-C-1 cells infected with vA25-A26+ and transfected with plasmids expressing 
ATIp and truncation mutants were resolved by SDS-PAGE under reducing 
conditions, transferred to a nitrocellulose membrane, and detected by 
chemiluminescence after probing with antibody to the HA epitope tag. The positions 











3.3.4 Effects of N- and C- terminal truncations of ATIp on inclusion formation. 
The inability of VACV expressing the C-terminally truncated A25p to form 
inclusions and the repair of this defect by substituting the CPXV ATIp suggested the 
importance of the added repeats. To map the domains of ATIp required for inclusion 
formation and occlusion, HeLa cells were infected with vA25-A26+ and transfected 
with the panel of plasmids shown in Figure 3-4A. Cells were fixed at 16 h after 
transfection, immunostained, and analyzed by confocal microscopy. The results of 
these experiments are summarized in Table 2 and confocal microscopy images of 
selected mutants are shown in Figure 3-5. In this section, I discuss the effects of the 
mutations on inclusion body formation; the effects on A26p and MV localization are 
noted in the following section. Typical inclusion bodies with ring-like antibody 
staining formed in all cells transfected with pATIpHA (Figure 3-5). N-terminal 
truncations of ATIp up to the repeats did not abrogate inclusion formation, although 
inclusions had an altered architecture appearing as lamellar structures (Figure 3-
5:pΔN1-100HA; pΔN1-300HA; pΔNcc1/2/3HA) that sometimes occupied the bulk of 
the cytoplasm (data not shown). However, deletion of the first four repeats plus the 
first 6 amino acids of repeat 5 (pΔNRep1-4’) disrupted inclusion formation even 
though the protein still contained nine intact repeats (Figure 3-5).  
The C-terminal truncation mutants were analyzed similarly. Truncation 
through repeats 12-14 did not alter architecture of inclusion bodies (not shown). 
Inclusions formed by ATIp truncation through repeats 10 and 11 also resembled wild-
type inclusions in shape, but staining revealed a greater amount of unincorporated 







Figure 3-5. Effects of ATIp mutations on inclusion formation, A26p localization, 
and MV occlusion. BS-C-1 cells were infected and transfected as described in the 
legend to Fig. 4. Representative confocal microscopic sections of selected N- and C- 
terminal deletion mutant ATIps are shown. Rabbit anti-HA antibodies followed by 
Alexa-594 conjugated anti-rabbit IgG were used to identify inclusion bodies. Mouse 
anti-V5 antibodies followed by Alexa-647 conjugated anti-rabbit IgG were used to 
visualize A26pV5. MVs were detected by YFP fluorescence due to A4 fusion protein. 




terminal end of ATIp, the inclusions became smaller, less discrete, and were detected 
in a lower percentage of cells e.g. 60%, 32%, 22% and 8% of cells transfected with 
pΔCRep9-14, pΔCRep8-14, pΔCRep7-14, and pΔCRep6-14, respectively (Figure 3-
5). The pΔCRep8-14HA and pΔCRep7-14HA proteins formed small, irregular 
inclusion bodies (Figure 3-5 and not shown). The pΔCRep6-14HA localization in the 
cell resembled that of A25HA (Figure 3-5). These results demonstrated a role for the 
N-terminal sequence of ATIp as well as repeats 1-4 (and possibly the first 6 amino 
acids of repeat 5) plus an additional 3 or more repeats of ATIp for inclusion 
formation. 
3.3.5 Effects of N- and C-terminal truncations of ATIp on A26p association and 
occlusion. 
In the experiments described above, A26p and MV localization were also 
examined. The first 100 amino acids of ATIp were dispensable for ATIp-A26p 
colocalization, even though the inclusions had an atypical appearance (Fig. 5, Table 
2). However, the truncated ATI proteins pΔN1-300HA through pΔNRep1-4’HA did 
not co-localize with A26p demonstrating that ATIp-A26p interactions are mediated 
through the N-terminal half of the ATIp protein (Figure 3-5, Table 3-2). Furthermore, 
mutations that disrupted the ability of ATIp to interact with A26p disrupted MV 
occlusion as determined by A4p:YFP fluorescence (Figure 3-5, Table 3-2). Although 
A26p localized to inclusion bodies formed by pΔN1-100HA, MVs were not 
embedded in those bodies (Figure 3-5), perhaps due to the aberrant structure of the 
ATIs. A26p and MV localized to the C-terminal mutants of ATIp that retained the 
ability to form inclusion bodies (Figure 3-5, Table 3-2).  




Table 2. Summary of the effects of deletion mutations on inclusion formation, 










ΔN1-100HA + + - 
ΔN1-300HA + - - 
ΔN1-412HA + - - 
ΔNcc1HA + - - 
ΔNcc1/2HA + - - 
ΔNcc1/2/3HA + - - 
ΔNRep1-4’ -  -* NA 
ΔCRep5-14HA -  +* NA 
ΔCRep6-14HA -  +* NA 
ΔCRep7-14HA +/-  +* NA 
ΔCRep8-14HA +/- + + 
ΔCRep9-14HA + + + 
ΔCRep10-14HA + + + 
ΔCRep11-14HA + + + 
ΔCRep12-14HA + + + 
ΔCRep13-14HA + + + 
ΔCRep14HA + + + 
ΔC1141-1284HA + + + 
 
 
aApproximately 100 cells infected with vA25-A26+ and transfected with plasmids 
expressing mutant ATIps were scored in at least two separate experiments. Inclusion 
formation was scored as +, +/-, or – based on the number of cells expressing the 
mutant protein that contained inclusion bodies: +, >50% cells contain inclusion 
bodies; +/-, <50% but >20%; -, <20%.  
bA26 and MV localization were scored as + or –. NA, not analyzed. 
*Proteins that did not form inclusion bodies or formed few inclusion bodies were 





with ATIps that formed inclusions because of solubility problems even in the 
presence of non-denaturing detergents. However, I could employ 
immunoprecipitation to determine whether soluble ATIp mutants that did not form 
inclusion bodies were able to interact with A26p. BS-C-1 cells were infected with 
vA25-A26- and co-transfected with pA26V5 and plasmids expressing the N-terminal 
ATI truncations pΔNRep1-4’HA or the C-terminal ATI truncations pΔCRep5-14HA, 
pΔCRep6-14HA, or pΔCRep7-14, respectively. Detergent-disrupted cell lysates were 
incubated with mouse anti-V5 conjugated agarose beads to bind A26p and associated 
proteins, and unbound and bound fractions were resolved by SDS-PAGE and 
analyzed by Western blotting. The C-terminal truncated proteins pΔCRep5-14HA, 
pΔCRep6-14HA, and pΔCRep7-14 were associated with A26p and present in the 
bound fractions (Figure 3-6).  However, the N-terminal truncated protein, pΔNRep1-
4’HA, was absent from the bound fraction and present only in the unbound fraction 
confirming that A26p-ATIp interactions are mediated by the N-terminus of the ATIp 
(Figure 3-6).  
3.3.6 A27p is required for congregation of MVs in inclusion bodies but not for 
localization of A26p. 
VACV A27p anchors A26p to the MV particle through disulfide interactions 
with the C-terminus of A26p [219, 220]. The association of the VACV A25p with the 
A26p-A27p complex suggested that A26p bridges MV with inclusion bodies through 
interactions with A27p on the MV membrane and ATIp, respectively. To test whether 
A27p is required for occlusion, I infected cells with the A27 deletion mutant vA27- 
(Table 3-1), which lacks an intact ATI gene and contains A4:YFP, and transfected 










Figure 3-6. Coimmunoprecipitation of truncated ATIps with A26pV5. Cells were 
infected with vA25-A26- and cotransfected with pA26V5 and plasmids expressing an 
N-terminal (ΔNRep1-4’HA) or C-terminal (ΔCRep5-14HA, ΔCRep6-14HA, 
ΔCRep7-14) ATIp truncation mutants that do not form inclusion bodies. Cells lysates 
were cleared and incubated with mouse anti-V5 conjugated affinity agarose beads. 
Unbound (U) and bound fractions eluted from beads with LDS sample buffer (B) 
were resolved by SDS-PAGE, transferred to nitrocellulose membrane, and probed 
with mouse anti-HA antibody to detect ATIp (upper panels) and mouse anti-V5 
antibody (lower panels) to detect A26p. Positions of 97- and 66-kDa marker proteins 






plasmids expressing HA-tagged A27p. ATIpFLAG formed inclusion bodies when 
transfected into cells infected with vA27-. However, the YFP fluorescent MV 
particles did not localize in inclusion bodies in the absence of A27p (Figure 3-7A). 
Occlusion was not rescued in cells infected with vA27- and transfected with a plasmid 
over expressing A26V5p in addition to ATIpFLAG, although A26V5p did localize to 
inclusion bodies under these conditions (Figure 3-7A). The ability of MV to embed 
within inclusion bodies in cells infected with vA27- was rescued by A27p expressed 
from plasmids co-transfected with pATIpFLAG and pA26V5 (Figure 3-7A). The data 
indicated a role for A27 in occlusion, likely by tethering A26p to the MV membrane. 
The above experiment also demonstrated that A26p could traffic to inclusions 
in the absence of MVs. To confirm this result, cells were infected with vATI+A26+ 
for 9 h in the presence of the drug rifampin, which interrupts assembly at a stage prior 
to crescent membrane formation [223, 224]. A26p localized to inclusion bodies in the 
absence of virion assembly, demonstrating that A26p traffics to inclusions in the 
absence of MV-association (Figure 3-7B). 
 
3.3.7 The MV anchoring domain of A26p is required but not sufficient for 
occlusion. 
I previously determined that the C-terminal 100 amino acids of A26p are 
required for A26p-A27p disulfide interactions and anchoring to the MV membrane 
[219]. Subsequently, it was shown that two conserved cysteines in the A26p C-
terminus specifically mediate A26-A27 interactions [20]. I employed two previously 
characterized truncated A26p mutants to test whether anchoring to the MV membrane 
















Figure 3-7. Requirement for A27p for virion occlusion. (A) HeLa cells were 
infected with an A27-deletion VACV expressing YFP fused to the core protein A4 
and lacking an intact ATI gene (vA27-, Table 1). Cells were transfected with 
pATIFLAG alone (top row), pATIFLAG and pA26V5 (middle row), or pATIFLAG, 
pA26V5 and pA27HA (bottom row). At 18 h after transfection, cells were fixed and 
permeabilized. ATIp (red) was detected with mouse anti-FLAG antibodies followed 
by Alexa 405 conjugated anti-mouse IgG. The A27pHA (magenta) and A26pV5 
(white) proteins were visualized using rat anti-HA and rabbit anti-V5 antibodies 
followed by Alexa 647- and Alexa 594-conjugated anti-rat and anti-rabbit IgG, 
respectively. MVs were detected by YFP fluorescence (green). (B) Cells were 
infected with vATI+A26+ for 9 h in the presence of the drug rifampin, which blocks 
virion assembly. ATIpHA (red) and A26pV5 (white) were visualized using rat anti-
HA and rabbit anti-V5 antibodies followed by Alexa 405 and -594, respectively. MVs 




expresses the C-terminal 270-500 amino acids of A26p and is sufficient for 
interaction with A27p, whereas pA26∆CV5, which codes for amino acids 1-409 of 
A26p, is not. Cells were infected with the A25p and A26p double deletion virus 
expressing A4:YFP (vA25-A26-) and co-transfected with pATIHA and pA26V5, 
pA26∆CV5, or pA26∆NV5. Cells infected with vA25-A26- and co-transfected with 
pATIHA and pA26V5 contained inclusion bodies to which A26pV5 and virions 
localized (Figure 3-8). A26∆CpV5 localized to inclusion bodies but was not 
associated with virions demonstrating that A26-MV anchoring is required for the 
occlusion of MV within inclusion bodies. In contrast, A26∆NpV5 was strongly 
coincident with virions, but neither A26∆NpV5 nor MV localized to inclusion bodies 
(Figure 3-8) suggesting that the N-terminus, although dispensable for A26p-A27p 
interactions, was required for association with inclusion bodies.  
3.4 Discussion 
The embedding of virions in dense proteinaceous masses is a strategy used by 
some DNA viruses to enhance their stability upon release into the environment. This 
capability is preserved by some orthopoxviruses but lost by others. Previous studies 
had shown that CPXV inclusions consist predominantly or exclusively of the 160 kDa 
ATIp [151]. However, some CPXV mutants that have an intact ATIp and can form 
inclusions fail to occlude virions. This defect is due to a mutation of the CPXV 
homolog of the VACV A26p [160]. Nevertheless, how A26p mediates occlusion was 












Figure 3-8. Requirements of A26p N- and C-terminal domains for virion 
occlusion. HeLa cells were infected with vA25-A26- and transfected with pATIpHA 
and cotransfected with pA26V5, pA26ΔCV5, or pA26ΔNV5. At 18 h after 
transfection, ATIpHA (red) was stained with rat anti-HA antibodies followed by 
Alexa 405 conjugated anti-mouse IgG, and A26pV5 and mutants (white) were 
visualized using rabbit anti-V5 followed by Alexa 594-conjugated anti-rabbit IgG. 
MV localization was monitored using A4p:YFP fluorescence (green). Blue, DAPI. 







A27p--A17p complex and the truncated VACV ATIp homolog A25p, suggested a 
bridging role for A26p in occlusion [219].  
I explored the validity of the above occlusion model using recombinant 
VACV rather than CPXV for two main reasons. First, VACV is better characterized 
than CPXV and more mutants and reagents are available. Second, I wanted to 
determine whether restoration of the full length ATIp would be sufficient for 
occlusion as well as inclusion formation in VACV-infected cells. If restoration of the 
ATIp failed to allow occlusion, then it would suggest a role for additional viral 
proteins. Remarkably, exchanging the truncated A25p of VACV-WR with the full-
length ATIp of CPXV-BR was sufficient for inclusion formation as well as occlusion 
of MVs. Indeed the VACV ATI were indistinguishable from CPXV ATI by electron 
microscopy.  
A panel of plasmids expressing ATIp mutants was constructed to investigate 
the domains needed for inclusion formation, interaction with A26p, and occlusion of 
MVs. Mutational analysis of ATIp revealed that domains essential for inclusion 
formation are contained in the C-terminal ATI repeat region of the protein. Inclusion 
formation required ATI repeats 1-4 and possibly the first 6 amino acids of repeat 5, 
which are present in A25p, plus at least three additional repeats. In general, a higher 
percentage of cells formed inclusions with more ATI repeats. N-terminal deletions of 
ATIp did not prevent inclusion body formation but their appearance was altered and 
lamellar structures were observed. I found that the N-terminal region of ATIp was 
needed for interaction with A26p. Even though deletion of the entire repeat region of 




with A26p as determined by both microscopic localization studies and 
immunoprecipitation experiments. Furthermore, mutations in ATIp that prevented its 
interaction with A26p also blocked occlusion indicating an essential role for A26-
ATIp interactions. Our data suggest that multiple ATI repeats are needed for 
aggregation of ATIp to form inclusions and that the N-terminal region of ATIp is 
needed for interaction with A26p. 
I further investigated the need to anchor A26p to the MV particle for 
occlusion. Initial characterization of occlusion by Shida et al. [225] suggested that the 
p4c protein, subsequently shown to be A26p [160], functions to mediate occlusion as 
a virion component. Since I had shown that A26p is anchored to the MV by the 
A27p-A17p complex, I predicted that A27p would be required for occlusion. Indeed, 
A26p was not sufficient to direct occlusion in the absence of A27p. Moreover, an 
A26p C-terminal deletion mutant that does not interact with A27p did not mediate 
occlusion. Nevertheless, the mutant A26p still localized to inclusion bodies, even 
though it was not associated with virus particles, suggesting that the N-terminus of 
A26p interacts directly with ATIp. On the other hand, an N-terminal deletion mutant 
of A26p that does not disrupt A26p-A27p interactions localized to virions in the 
cytoplasm of infected cells but was unable to mediate occlusion or localize to 
inclusion bodies. 
Our studies indicated that A26p has a bridging function enabling the 
association of MVs containing membrane-associated A27p with the ATIp in 
inclusions. This model can explain why immature virions are not occluded since 




scaffold has been removed [91]. The large size of MVs and the distance between the 
sites of their assembly in factories and inclusion bodies make it unlikely that 
occlusion is a totally passive phenomenon. McKelvey et al. [160] suggested that 






Chapter 4: Formation of orthopoxvirus cytoplasmic inclusion bodies 
by in situ mRNA translation and the requirement of microtubules for 
their coalescence and occlusion of virions 
 
4.1 Introduction 
Poxviruses subvert the host cell infrastructure to create microenvironments in 
which viral and host proteins are sequestered for the regulation of distinct stages of 
the viral life cycle. Poxvirus transcription, genome replication, and assembly occur 
entirely in the cytoplasm of infected cells at organized, endoplasmic reticulum (ER)-
bound bodies called viral factories (VFs) [79, 80, 83, 226]. Studies using vaccinia 
virus (VACV), the most characterized member of the orthopoxvirus genus, showed 
that VFs contain tunnel-like subdomains in which viral mRNAs and transcription 
factors localize [79]. In addition, translation initiation factors eIF4E and eIF4G and 
ribosomal proteins are recruited to these VF subdomains for the synthesis of viral 
proteins [79]. Consequently, VFs efficiently localize the components necessary for 
the assembly of progeny mature virions (MVs).  
MVs consist of genomic DNA and enzymes necessary for early transcription 
packaged in a multi-protein core surrounded by a lipoprotein membrane [84]. A 
population of MVs segregates to sites at the trans-Golgi network (TGN) or late 
endosomes where they acquire two extra membranes to form the triple-membrane 
wrapped virions (WVs). WVs are transported to the periphery of the cell and 
exocytosed, losing the outermost membrane to become double-enveloped 
extracellular virions (EVs). Most MVs, however, are not destined to become EVs, but 




orthopoxviruses, including strains of cowpox (CXPV), ectromelia (ECTV), fowlpox, 
and raccoonpox, embed MVs in cytoplasmic, proteinaceous matrices called A-type 
inclusion (ATIs) [146-149], which are thought to provide protection after release into 
the environment. ATIs are composed of a single viral polypeptide, the ATI protein 
(ATIp)[151]. ATIp is a large protein (160-kDa in CPXV) containing C-terminal, 
highly hydrophobic repeats [151, 154] that are required for inclusion body assembly 
[227].  
 ATIs are localized throughout the cytoplasm and increase in size during 
infection. In electron microscopy studies of sections from cells infected with CPXV, 
polyribosomes and protein pulse-labeled with 3H-leucine were seen associated with 
the peripheries of ATIs [153]. Attempts to identify RNA associated with the 
polyribosomes surrounding ATIs suggested that the RNA was most likely viral in 
origin [153]. However, the specific RNA associated with ATIs was not identified. 
The A26 protein (A26p) is required for the embedment of MV within ATIs [160, 
227]. A26p is an MV-specific protein anchored by disulfide bond mediated protein-
protein interactions with the A27p-A17p complex to the MV membrane [20, 219, 
220].  
 Orthopoxviruses hijack the cytoskeleton for entry, intracellular transport, and 
exit from the host cell. Modulation of the actin cytoskeleton facilitates virus entry 
[228], after which viral cores rapidly associate with microtubules facilitating 
migration to a juxtanuclear position [43, 229]. Progeny MVs traffic on microtubules 
to sites of wrapping [107, 108], and WVs use microtubules to move to the plasma 




at the cell surface for cell-to-cell dissemination [140]. Given their size (~360 X 270 X 
250 nm), it is likely that the association of MVs with inclusion bodies is also 
dependent on active transport using the cytoskeleton. McKelvey et al. proposed that 
A26p might have a role in directing transport of MV from VFs to ATIs during 
occlusion [160]. 
Orthopoxviruses such as VACV that do not form ATI may encode a C-
terminally truncated ATIp, A25p [231, 232]. I demonstrated that VACV could make 
ATI and occlude MVs if the CPXV ATIp gene was substituted for the mutated 
VACV homolog (14). As much more is known about the molecular biology of VACV 
than CPXV or other orthopoxviruses than make ATI naturally, I have used the 
reconstructed VACV system to study ATI formation and the mechanism of occlusion. 
I demonstrated that the direct association of A26p with both the A27p-A17p complex 
and the ATIp is required to mediate occlusion [227]. In the present study, I show that 
ATI enlargement is dependent on both new protein synthesis and coalescence of 
smaller ATI. mRNA encoding ATIp and the translation initiation factor, eIF4E, were 
localized to ATIs, indicating the existence of a mechanism for specific mRNA 
trafficking from transcription sites in the VF. Both the coalescence of ATI and 
occlusion required intact microtubules, and MVs move to ATIs at speeds 
characteristic of microtubular transport.  
4.2 Methods and materials 
4.2.1 Cells and virus infection. 
HeLa, African green monkey kidney BS-C-1, and rabbit kidney RK13 cells 




Gaithersburg, MD) containing 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml 
streptomycin, and 10% fetal bovine serum (FBS).  Virus infections of cells were 
carried out in medium as described above except for 2.5% FBS. VACV strain 
Western reserve (WR) and all recombinant viruses were propagated as previously 
described. 
4.2.2 Recombinant viruses and plasmids. 
The recombinant VACVs used in this study were described previously (ref). 
Briefly, vATI+A26+.A4:YFP is a recombinant VACV expressing a C-terminally HA-
tagged CPXV ATIp (ATIpHA) and a C-terminally V5-tagged VACV A26p 
(A26pV5). vA25+A26+.A4:YFP expresses an HA-tagged VACV A25p (A25pHA) 
and A26pV5. vA25+A26-.A4:YFP expresses A25pHA but with the A26 gene deleted. 
In the above viruses, A4:YFP denotes the fusion of the A4 gene in frame with the 
gene expressing the yellow fluorescent protein (YFP). vA25-A26+ is an A25-deletion 
virus and expressing A26pV5. vA25+A26+, vATI+A26+, vATI+A26- are as described 
above but the A4 gene was not fused to YFP. 
 To construct the plasmid pATIAU1, the ATI gene was amplified using 
Accuprime Pfx (Invitrogen, Carlsbad, CA) from CPXV-BR genomic DNA with a 
forward primer to the ATI promoter and reverse primer coding for the AU1 epitope 
tag (DTYRYI) and blunt-end ligated into pCR-BluntII-TOPO (Invitrogen). 
4.2.3 Antibodies for immunofluorescence. 
Both rabbit polyclonal antibodies (PAbs) and mouse monoclonal antibodies 




studies at a 1:250 dilution (Covance, Princeton, NJ). Mouse anti-AU1 (DTYRYI) 
antibodies (Covance) were used at a 1:250 dilution. Mouse anti-puromycin (PMY) 
MAb 12D10 was used at 1:100 and was provided by Alexandre David from the 
laboratory of Jonathan Yewdell and Jack Bennink. Mouse anti-eIF4E was obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA) and was used 1:100. All Alexa 
Fluors conjugated anti-IgG were obtained from Invitrogen and used at dilutions of 
1:250.  
4.2.4 Preparation for confocal microscopy. 
For confocal imaging of fixed cells, 24-well dishes containing 12 mm 
coverslips seeded with HeLa cells were infected at a multiplicity of infection (moi) of 
0.1 PFU per cell in EMEM (Quality Biological) and incubated with rocking at room 
temperature for 1 h. Following adsorption, the inoculum was removed and the cells 
were incubated at 37°C. Cells were washed twice in Dulbecco’s phosphate-buffered 
saline (PBS) and then fixed with 4% paraformaldehyde for 15 min. Cells were 
washed with PBS, permeabilized with 0.2% Triton X-100 in PBS for 7 min, washed 
(4 X 5 min) in PBS, and blocked with 10% FBS diluted in PBS. Primary antibodies 
and secondary Alexa Fluor-conjugated IgG were diluted as described above in 10% 
FBS/PBS and incubated with cells for 1 h and 45 min, respectively, at 37°C. Labeling 
with anti-eIF4E antibody was carried out as above except blocking and antibody 
incubation steps were in 1% bovine serum albumin, and cells were incubated with 
anti-eIF4E antibody overnight at 4°C. Cover slips were mounted using ProLong Gold 
mounting medium containing 4’, 6’-diamidino-2-phenylindole (DAPI) from 




München, Germany) were seeded with HeLa cells and infected at an moi of 0.1 
PFU/cell for 1 h. The inoculum was removed and medium containing 10 µM ST-246 
was added. 
4.2.5 Fluorescence in situ hybridization (FISH). 
An antisense probe to the nucleotide sequence encoding the HA tag was 
synthesized and conjugated to Alexa-594 (5’-/5Alex594N/TCA GGC GTA CTC 
GGG CAC GTC GTA GGG GTA-3’) by Integrated DNA technologies (IDT) 
(Coralville, IA). FISH was carried out per the Singer lab online protocol 
(http://www.singerlab.org/protocols). Briefly, coverslips containing 
vATI+A26+.A4:YFP- or vA25-A26+.A4:YFP- infected cells were fixed and 
permeabilized using 70% ethanol overnight at 4°C. Hybridization was carried out at 
37°C overnight in 40 µl hybridization buffer containing 2 mM vanadyl-ribonuclease 
complex, 0.02% RNAase-free bovine serum albumin, 100X E. coli tRNA (Roche 
Applied Sciences, Indianapolis, IN), 2XSSC (300 mM NaCl, 30 mM sodium citrate, 
pH 7.0), 50% formamide, and 40 ng of probe. Cells were washed 2X in 2XSSC for 30 
min at 37°C.  
4.2.6 PEGylation experiments. 
HeLa cells (1X12-well per cover slip) were infected with vA25-A26+ and 
transfected with pATIAU1 using Lipofectamine 2000 per the manufacturers 
instructions (Invitrogen); HeLa cells on coverslips were infected with 
vATI+A26+.A4:YFP. 4 hpi, the cells infected with vA25-A26+ and transfected with 




were centrifuged for 10 min at 1500 x g at room temperature. The EMEM was 
aspirated and cell were incubated in 250 µl of the polyethylene glycol (PEG) solution 
containing a 10% DMSO in 50% (w/v) PEG (Av. Mol. Wt. 1450) (Sigma-Aldrich, St. 
Louis, MO) in DPBS without calcium. 
4.2.7 Puromycin labeling. 
Method provided by Alexandre David (publication in submission). 
4.2.8 Confocal microscopy and image processing. 
For fixed cell imaging, a Leica SP2 inverted four-channel microscope was 
used. A Leica SP5 inverted 5-channel confocal microscope with high speed scanning 
using a resonant scanner was used for live imaging experiments. Cells were imaged 
on a stage containing an incubation chamber that maintained cells at 37°C with 5% 
CO2. Representative images and time series were deconvolved using Huygens 
Essential version 3.5.0, 64 bit (Scientific Volume Imaging, Hilversum, Netherlands). 
Z-sections were reconstructed as 3D images using IMARIS Bitplane Scientific 
Software version 7.0 (Saint Paul, MN) using surpass mode with an orthogonal view. 
The IMARIS Spots feature was used to track MV in 4D (X, Y, X, and time[t]) and to 
extract statistical  analyses of particle dynamics. 
 
4.3 Results 
4.3.1 Time course of ATIp synthesis and ATI formation. 
ATIp is a highly expressed late protein and CPXV inclusion bodies are visible 




high sensitivity and resolution provided by immunofluorescent confocal microscopy 
to monitor ATIp synthesis using a previously characterized recombinant VACV that 
expresses the CPXV-BR ATI protein with a C-terminal HA tag and the A4 protein 
fused to YFP  (vATI+A26+.A4:YFP). HeLa cells were infected with 
vATI+A26+.A4:YFP and fixed at 3-, 5-, 7-, 9-, and 11 hpi, and ATIp localization was 
monitored using anti-HA antibody. VFs were stained with DAPI and appear as 
amorphous juxta-nuclear bodies that appear compact early in infection and less 
structured at later time points (Figure 4-1). The core protein, A4p, fused to YFP was 
used as a control to monitor protein synthesis in VFs [79]. Numerous punctate bodies 
containing ATIp were distributed throughout the cell as early as 3 hpi, whereas 
A4p:YFP was in or adjacent to VFs (Figure 4-1). By 5 hpi, although A4p:YFP was 
detected throughout VFs, ATIp was not seen in VFs in any of the infected cells 
viewed (n=50). The ATI were larger than those seen at 3 hpi and had a characteristic 
donut appearance due to peripheral antibody staining (Figure 4-1). ATIs continued to 
increase in size throughout infection as previously observed, although some small 
inclusions were still seen at 9 h (Figure 4-1, arrowheads). MVs were at the periphery 
of ATIs at 7 hpi but were dispersed throughout the bodies at 11 hpi (Figure 4-1, lower 
panels).  
4.3.2 ATI mRNA is translated at inclusion bodies. 
Previous studies provided evidence for the synthesis of VACV late proteins 
within subdomains of the VF in which viral RNA and cellular translation factors were 
localized. The absence of ATIp in VFs (Figure 4-1) combined with previous studies 
















Figure 4-1:  Time course of ATI formation.  Representative confocal images of 
Hela cells infected with vATI+A26+ and fixed at 3-, 5-, 7-, 9-, and 11 hpi. Rabbit anti-
HA antibodies, followed by Alexa-568 conjugated anti-rabbit IgG, were used to 
visualize ATIpHA (red, Alexa-568). A4p:YFP (green) was monitored using YFP 
fluorescence. The nucleus and viral factories (VF) were visualized by DAPI staining 
(blue). Arrow indicates ATIpHA coincident with A4:YFP at the VF, and arrow heads 












inclusion bodies [153] led us to investigate whether ATI mRNA is translated at 
inclusion bodies. The translation initiation factor eIF4E, which binds the 5’ cap of 
mRNAs [234], was previously shown to localize within VF subdomains at 8 hpi in 
cells infected with VACV that does not form ATI. To determine whether eIF4E might 
be recruited to inclusion bodies, I infected HeLa cells with vATI+A26+.A4:YFP for 8 
h and looked for the coincidence of anti-HA and anti-eIF4E staining. Cells were 
observed by confocal microscopy and scored for localization of eIF4E to both VFs 
(arrowheads) and inclusion bodies (arrows). eIF4E localized to VFs and/or inclusion 
bodies in 73% and 76% of cells (n=30), respectively (Figure 4-2A). This result 
suggested that translation was occurring in ATIs as well as in VFs. 
 Having shown that eIF4E was recruited to inclusion bodies, I next sought to 
determine whether active translation was occurring there. I addressed this question by 
employing an assay similar to the one developed by Schmidt et al (2009) that uses 
puromycin followed by fluorescent puromycin antibody to stain actively translating 
ribosomes [235]. Puromycin inserts at the A-site of ribosomes and is covalently 
linked to the growing, C-terminal end of nascent peptides causing cessation of 
translation [236, 237].  HeLa cells were infected with vATI+A26+.A4:YFP for 22 h, 
treated with puromycin, and then fixed. Mouse anti-puromycin MAb and rabbit anti-




















Figure 4-2:  Translation and ATIp mRNA localization at ATIs. (A) Images of 
Hela cells infected with vATI+A26+.A4:YFP and processed 8 hpi for immunostaining 
using antibodies against eIF4E (green, Alexa-568) and the HA-tag on the ATIp (red, 
Alexa-647). The nucleus and viral factories (VFs) were visualized by DAPI staining 
(blue), and MVs were localized using A4-YFP-fluorescence (white). Cells were 
monitored for localization of eIF4E to VFs (arrowheads) and/or ATIs (arrows). Bar 
graph shows percent localization of eIF4E to VFs and/or ATIs in ten cells from three 
independent studies. Error bars, SEM. (B) 3D reconstruction of Z-sections from a 
vATI+A26+.A4:YFP-infected Hela cell labeled with puromycin (PMY) 22 hpi. 
Labeled cells were permeabilized with digitonin, fixed, and stained with mouse anti-
PMY antibody (green, Alexa-568). ATIs were visualized using rabbit anti-HA 
antibodies (red, Alexa-647). Blue, DAPI; white, A4p:YFP. (C) In situ hybridization 
of ATIHA mRNA using an Alexa-594 labelled antisense oligonucleotide probe (red) 
specific to the HA tag. vATI+A26+.A4:YFP-infected Hela cells were fixed 12 hpi 
when ATIs could be visualized by YFP-fluorescence (white) from embedded MVs. 









respectively. Anti-puromycin and anti-HA (ATIp) staining were coincident 
supporting the conclusion that active translation occurs at ATI (Figure 4-2B). 
I next sought to determine whether ATIp mRNA is associated with ATI. I 
designed an anti-sense oligonucleotide probe conjugated to Alexa-594 specific to the 
HA tag that was fused to the ATIp and performed fluorescence in situ hybridization 
on cells infected for 12 h with vATI+A26+.A4:YFP. ATIs were identified using 
A4p:YFP fluorescence of embedded MVs. The HA probe labeled ATIs, although 
some signal was detectable in cytoplasm and coincident with virions (Figure 4-2C). 
Taken together, the data indicate that ATIp mRNA is translated at inclusion bodies. 
4.3.3 Enlargement of ATIs is due to protein synthesis and ATI coalescence. 
As the ATIs increased in size, I noted that their number appeared to decrease. 
To quantify this impression, I measured the diameters of inclusion bodies and 
determined their number during the course of infection. HeLa cells were infected with 
vATI+A26+.A4:YFP and fixed at 5-, 7-, 9-, and 11 hpi. Inclusion bodies were 
visualized using anti-HA staining of the fixed cells, which were imaged as Z-stacks. 
IMARIS Bitplane software was used to measure the diameter of each ATI in the Z-
section at which the diameter was greatest. The lowest threshold of ATI diameters 
was set at 0.3  µm given the limits of resolution; therefore, ATIs that measured less 
than 0.3 µm in diameter were not scored. The mean size of ATIs increased from 
0.66±0.02 to 1.36±0.04 from 5 to 11 hpi, respectively (Figure 4-3A). During the same 
time, the mean number of ATIs in infected cells decreased (Figure 4-3A). Plotting the 
distribution of  individual  ATI diameters  provided further insight. At 5 hpi, inclusion 







Figure 4-3:  Time course of ATI diameter and number.  Cells were infected with 
vATI+A26+ and fixed at 5-, 7-, 9-, and 11 hpi. Twenty five cells in two independent 
experiments were imaged as Z-stacks by confocal microscopy, and ATI diameters 
were measured at the largest diameter in section using Imaris Bitplane software. Only 
ATI ≥ 0.3 µm in diameter were enumerated. (A) The mean number of ATIs was 
compared to the mean size as expressed as diameter (µm) for several time points. 
Error bars represent the means ± the standard error of the means (SEM) of duplicate 
experiments. (B) The distribution of the diameters of the all of ATIs monitored from 
the two experiments were graphed for each time point. 365, 295, 258, and 307 




(Figure 4-3B). By 7 hpi, the main peak shifted indicating the population as a whole 
had larger diameters, however the distribution was more heterogeneous than at 5 hpi. 
At 9 and 11 hpi, larger diameter ATIs predominated (Figure 4-3B). The data 
suggested that the increase in ATI size and reduction in number were due to 
coalescence as well as ATIp synthesis and that new ATIp continued to form. 
I next examined the effects of blocking protein synthesis on the formation of 
ATI. I infected HeLa cells with vATI+A26+.A4:YFP, and after 5 h replaced the 
medium with either untreated medium or medium containing cycloheximide (CHX), 
an inhibitor of protein synthesis. Infected cells were incubated in the presence of 
CHX for an additional 4 and 6 h and then fixed at 9 and 11 hpi, respectively. Anti-HA 
antibody was used to stain ATI, which were imaged as Z-stacks using confocal 
microscopy. ATI were enumerated and the diameters measured as described above. 
Frequency distributions of the diameters at both 9 and 11 hpi in cells incubated 
without CHX showed a peak shift relative to diameters at 9 and 11 hpi with CHX, 
demonstrating that new protein synthesis contributes to ATI size (Figure 4-4A, 
histograms). However, ATI diameters at 9 and 11 hpi from cells incubated with CHX 
were larger than ATI diameters from cells fixed at 5 hpi or time zero. Thus, ATI 
increased in size even in the absence of new protein synthesis (Figure 4-4A, 
histograms). In addition, the average inclusion body number per cell still decreased in 
the presence of CHX (Figure 4-4A, bar graphs).  
I considered that the changes in ATI size and number in the presence of ÇHX 
might be due to coalescence and require microtubules. Microtubules might also be 




















Figure 4-4:  Contribution of new protein synthesis and microtubules to ATI size 
and number.  (A) Histograms showing frequency distributions of ATIs (µm) in the 
presence and absence of cycloheximide (CHX). Bar graphs showing the effects of 
CHX on average ATI number per cell. Hela cells were infected with 
vATI+A26+.A4:YFP and ATIs at 5-, 9-, and 11 hpi were compared to ATIs from cells 
to which 10 µg/mL CHX was added at 5 hpi and fixed at 9 or 11 hpi [5+(CHX)-9 or -
11 hpi]. Data represents two separate experiments of 25 cells each. Error bars, SEM. 
(B) Histogram showing the effects of CHX alone or with 30 µm NOC on ATI size, 
and bar graph of the effects of CHX and NOC on the average ATI numbere per cell. 
Drugs were added to vATI+A26+.A4:YFP-infected Hela cells at 4 hpi (Time 0) and 
fixed at 9 hpi. Error bars, SEM. (C) Representative confocal images from 
experiments in (B). ATIs were visualized using rabbit anti-HA antibodies (red, 
Alexa-568), and microtubules (MT) were stained using both mouse anti-α- and 
mouse anti-β-tubulin antibodies (white, Alexa-647). Blue, DAPI; green, A4p:YFP. 




monitored ATI enlargement in the presence of the drug nocodazole, which 
depolymerizes microtubules. HeLa cells were infected with vATI+A26+.A4:YFP and 
at 4 hpi, were either fixed (time zero) or the media were replaced with media 
containing the following: (1) no drug, (2) nocodazole, (3) CHX, or (4) nocodazole 
plus CHX. The cells were incubated for an additional 5 h and fixed 9 hpi. At 4 hpi, 
there were numerous, small ATIs (Figure 4-4B and C).  The diameters distributed as a 
narrow peak suggested that ATIs were relatively homogenous in size (Figure 4-4B, 
histogram). By 9 hpi in medium without drugs, cells contained fewer ATIs (Figure 4-
4B, bar graph). ATI diameters distributed into multiple peaks indicating cells contain 
both small and large inclusion bodies (Figure 4-4B, histogram).  In contrast, treatment 
with nocodazole, which disrupted microtubules (Figure 4-4C), resulted in a one main, 
relatively narrow peak representing more uniform ATIs of smaller diameter (Figure 
4-4B, histogram). In addition, the cells treated with nocodazole contained large 
numbers of ATIs (Figure 4-4B, bar graph). As described above for Figure 4-4A, there 
was some increase in ATI size and reduction in number in the presence of CHX 
(Figure 4-4B). Incubation with both nocodazole and CHX, however, drastically 
reduced ATI diameters relative to treatment with medium containing no drugs and 
nocodazole or CHX alone (Figure 4-4B, histogram). The distribution peak resembled 
the peak of diameters in cells fixed at 4 hpi or time zero. With CHX and nocodazole, 
the mean number of ATIs per cell was slightly reduced compared to time zero 
reflecting the inhibition of new ATI formation and prevention of coalescence  (Figure 
4-4B, bar graph). The data suggest that both new protein synthesis and intact 




4.3.4 Further evidence for coalescence. 
The finding that ATI enlarge in size while the mean number per cell decreases 
between 5 and 9 hpi suggested that inclusion bodies might be merging together or 
coalescing by a microtubule-dependent mechanism. Visual evidence for coalescence 
is shown in a 3D reconstruction and sections of a Z-stack of adjacent ATIs in a HeLa 
cell infected with vATI+A26+.A4:YFP. The junction between ATIs appears 
continuous in sections 5-8 (Figure 4-5).  
To further test for ATI mixing, I used polyethylene glycol (PEG) to fuse two 
cell populations expressing differentially tagged ATIps. HeLa cells on cover slips 
were infected with vATI+A26+.A4:YFP, which expresses an HA-tagged ATIp. I next 
infected another population of HeLa cells with vA25-A26+, which does not express 
YFP fused to A4p, and transfected plasmids expressing the ATI gene with an AU1 
tag (pATIAU1). At 4 h after transfection, the cells expressing ATIpAU1 were scraped 
and spinoculated onto the cover slips containing the vATI+A26+.A4:YFP-infected 
cells and incubated with PEG to induce cell fusion. Following washout of PEG, the 
fused cells were incubated in medium with or without CHX for 12 h prior to fixation 
and staining with antibodies against the HA and AU1 epitope tags. Cells were 
scanned for A4p:YFP expression and AU1 staining to identify fused clusters, and the 
ATIs were imaged and measured as described for previous experiments.  
In cells fixed at 4 hpi immediately following PEG-fusion, representing time 
zero, anti-HA staining was not coincident with AU1 staining in fused cell clusters 
(Figure 4-6A). ATIpHA formed smaller inclusion bodies than those composed of 

















Figure 4-5:  Visualization of partially coalesced ATIs. Large panel shows a 3D 
reconstruction of 0.21 µm Z-sections through a cell containing adjacent ATIs. The 
optical sections are presented in panels 1-10. Hela cells were fixed after overnight 
infection with vATI+A26+.A4:YFP, and ATIs were visualized using rabbit anti-HA 
antibody (red, Alexa-568). Mouse anti-α- and -β-tubulin antibodies were used to stain 





















Figure 4-6:  Inclusion bodies coalesce in PEG-fused cells.  (A) Images of polyethylene 
glycol (PEG)-fused cells expressing HA-tagged ATI (red, Alexa-647) and AU1-tagged 
(green, Alexa-568) ATI proteins. 2.5X105 Hela cells were infected with vATI-A26+ and 
transfected with plasmids expressing the ATI protein with a C-terminal AU1 tag 
(pATIAU1). 4 hpt, the cells were scraped and added in the presence of 50% (w/v) PEG to 
vATI+A26+.A4:YFP -infected Hela cells on coverslips 4 hpi. Fused cells were either 
fixed (Time 0) or incubated at 37°C for 12 h in EMEM with or without CHX [16 hpi and 
16 hpi (+CHX), respectively]. Time zero and 16 hpi (+CHX) are 3D reconstructions of 
multiple Z-sections and 16 hpi and DIC images are 0.24 µm Z-sections. Blue, DAPI; 
magenta, A4p:YFP. Scale bars, 5 µm. (B) Frequency distribution of inclusion body sizes 
in PEGylated cell clusters. ATIpHA- and ATIpAU1-containing unmerged inclusion 
bodies were measured for Time 0. Merged inclusion body sizes in the presence or 
absence of CHX were measured for No drug and CHX, respectively. Bar graph shows the 
percent of fused cell clusters expressing both ATIpHA and ATIpAU1 that contained 





perhaps transfection resulted in a higher level of ATIpAU1 expression. In cell 
clusters fused and incubated in untreated medium for 16 h, ATIpHA and ATIpAU1 
staining was coincident in almost 70% of the cell clusters viewed (Figure 4-6B, bar 
graph and Figure 4-6C). At 16 h, the ATIs had increased in diameter and showed 
multiple peaks (Figure 4-6B, histogram). To eliminate the possible addition of ATIp 
monomers post-cell-fusion, the experiment was also carried out in the presence of 
CHX. About 44% of cell clusters contained inclusion bodies with coincidental anti-
HA and -AU1 staining providing evidence for coalescence (Figure 4-6B, bar graph). 
The inclusion bodies co-staining for HA and AU1 had smaller diameters than those 
incubated in the absence of CHX, consistent with the absence of ATIp synthesis in 
the fused cells (Figure 4-6, histogram).  
4.3.5 MVs use microtubules for embedment within inclusion bodies. 
I was interested in investigating MV movement to inclusion bodies. To this 
end, I infected HeLa cells with vATI+A26+.A4:YFP in the presence of 10 µm ST-246 
(4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-etheno-cyclo-
prop[f]isoindol-2(1H)-yl)-benzamide) to prevent the wrapping of MVs to form WVs, 
which traffic on microtubules [126]. Infected cells were imaged at 8 hpi, a time at 
which I could visually identify ATIs encrusted with YFP-fluorescing MVs. MV-
studded ATIs had a characteristically spherical pattern that was easily distinguishable 
from clusters of virions seen in cells infected with a wild-type VACV expressing 
A4p:YFP (data not shown). To track MVs I imaged in X, Y, and Z at 1 frame/1.573 s 




MVs that visibly adhered to inclusion bodies for at least ten time points following 
contact. MVs moved to inclusion bodies at an average speed of 0.501±0.637 (SEM) 
(Table 4-1), which is consistent for the transport of MV on microtubules [108]. 
Particle velocities alternated between fast and slow, but particles did not pause as 
often as MV observed moving between VFs and sites of wrapping [108].  
 To further investigate the movement of MVs to ATI, I infected HeLa cells 
with vATI+A26+.A4:YFP in the presence of rifampicin, which does not block 
inclusion body formation [152, 227] but reversibly prevents virus assembly [224, 
238].  After 10 h, the rifampicin was washed out and the cells were incubated either 
in the presence of cytochalasin D, which inhibits actin polymerization, or nocodazole 
for an additional 10 h. Cells were fixed and stained for ATIp using anti-HA 
antibodies, and occlusion was monitored using A4p:YFP fluorescence (Figure 4-7A). 
The effects of the drugs on microtubules and actin were visualized using both mouse 
anti-α- and anti-β-tubulin antibody staining and 594-phalloidin staining, respectively 
(data not shown). ATIs in randomly selected cells in three separate experiments were 
scored as positive (+) or negative (-) for occlusion (Figure 4-7A). Cytochalasin D 
caused cells to shrink and have a misshapen appearance but did not have a 
statistically significant effect on occlusion (Figure 4-7B). Nocodazole, however, 
decreased occlusion by a statistically significant level (Figure 4-7B), providing 





Frame-by-frame measurementsa for four individual virions 
 MV particle  
Frame no.b A B C D Frame no.b 
1 2.381 2.089 1.160 0.592 0.932 16 
2 1.267 0.450 0.875 0.248 0.603 17 
3  0.892 0.200 0.589 0.422 0.634 18 
4 0.587 0.253 0.277 0.705 0.541 19 
5 0.221 0.467 1.094 0.649 0.310 20 
6  0.399 0.234 0.893 0.362 21 
7  0.297 1.497 0.618 0.144 22 
8   0.456 0.432 0.473 23 
9   0.462 0.636 1.065 24 
10   1.178 0.490 0.831 25 
11   0.677 0.532 0.224 26 
12   0.705 0.866 0.957 27 
13   0.893 0.868 1.323 28 
14   0.393 0.474 0.338 29 
15    1.238 0.146 30 
No. Time points 5 7 14 25  
Total Time 7.865 11.011 22.022 39.325  
Total distance (µm) 5.348 4.156 10.491 18.547  
Average speed 
(µm/s) 0.680 0.377 0.476 0.472 
 
aMeasurements are displayed in µm; bFrame rate equals 1 frame/1.573 s  
 
Table 4-1:  Frame-by-frame measurements of four individual virions. 4D (X, Y, 
Z, and t) live cell imaging of MV trafficking to ATIs. HeLa cells were adsorbed with 
vATI+A26+.A4:YFP for 1 h at room temperature and then incubated for 8 to 10 h in 
EMEM containing 10 µm ST-246 to prevent WV formation. Particles and occluded 
inclusion bodies were visualized using YFP fluorescence. Imaris Spots software was 
used to track MV observed to associate with inclusion bodies for at least ten 














Figure 4-7:  Effects of cytoskeletal inhibitors on occlusion. (A) Representative 
confocal Z-section images of occluded (+) and non-occluded (-) ATIs. Rabbit anti-
HA antibodies were used to identify inclusion bodies (red, Alexa-594), and A4p:YFP 
fluorescence (green) was used to visualize MV particles. (B) Bar graph depicting the 
effects of cytoskeletal inhibitors on percent occlusion, which is the number of ATIs 
positive for virion occlusion relative to the total number of ATIs viewed. HeLa cells 
were infected with vATI+A26+.A4:YFP in the presence of 100 µg/ml rifampicin to 
inhibit virion morphogenesis. After 10 h, the rifampicin was removed and replaced 
with untreated medium (mock) or medium containing 30 µm nocodazole (NOC) or 1 
µm cytochaslasin D (CD) for an additional 10 h. Data represents two separate 






4.3.6 A26p is not required for MV movement but contributes to particle velocity. 
Previously, I observed that A26p associates with ATIs even in the absence of 
incorporation into MV particles [227]. Given the requirement of microtubules for 
occlusion, I next examined whether microtubules are required for A26p localization 
to ATIs. Cells were infected with vATI+A26+.A4:YFP for 4 h prior to the addition of 
medium containing nocodazole as not to inhibit movement of entering viral cores and 
establishment of VFs. At 16 hpi, cells were fixed, permeabilized, and stained using 
anti-V5 antibodies to localize A26p and anti-HA antibodies to visualize ATIs. Cells 
were selected at random and ATIs were scored for both MV and A26p localization 
(Figure 4-8B). As shown previously [227], in the absence of nocodazole A26p 
strongly colocalized with inclusion bodies and as well as unembedded virions (Figure 
4-8A, top panel). Almost 90% of ATIs viewed contained embedded MVs, and A26p 
localized to almost 100% of the ATIs viewed (Figure 4-8B). Furthermore, nocodazole 
did not disrupt A26p localization to inclusion bodies as seen in two representative 
images (Figure 4-8A). While nocodazole greatly disrupted MV embedment, A26p 
localized to almost 80% of the inclusion bodies studied (Figure 4-8B). A26p was also 
strongly localized to MV (Figure 4-8B, bottom two panels), which aggregate near 
factories in the presence of nocodazole.  
 The above data showing that A26p associates with ATIs in the presence of 
nocodazole suggest that A26p is not a movement protein for MVs. Nevertheless, I 
decided to examine MV particle dynamics in the absence of A26p to see if I could 
detect a defect in movement. HeLa cells were infected with a VACV expressing an 






















Figure 4-8:  Effects of nocodazole on localization of A26p to ATIs. (A) Media 
from vATI+A26+.A4:YFP-infected Hela cells were replaced 4 hpi with untreated 
medium (-NOC) or medium containing 30 µm NOC (+NOC) and incubated 
overnight. ATIs were visualized and enumerated using anti-HA antisera (red, Alexa-
647). A26pV5 (green, Alexa-568) and MV (white) were localized using anti-V5 
antibodies and A4p:YFP-fluorescence, respectively. Blue, DAPI. Scale bars, 5 µm. 
(B) Bars represent percent of inclusion bodies positive for MV and A26pV5 






VACV expressing an HA-tagged A25p (vA25+A26-.A4:YFP). Following adsorption, 
the medium was replaced with medium containing ST-246 to prevent WV formation 
and movement. At 7 to 8 hpi, MVs were live imaged in 4D using a Leica SP5 
inverted confocal microscope with a resonant scanner. Regions of interest in cells 
distal from factories and from aggregates of virions were visualized to allow tracking 
of individual particles. Tracking was carried out as described above using IMARIS 
“Spots” software, and the movement statistics of MV in the presence and absence of 
A26p were compared. The deletion of A26 did not affect overall track length, 
however, mean particle speeds were significantly reduced (Figure 4-9A, B).  
4.3.7 Occlusion does not sequester MV from wrapping. 
In early studies on occlusion, a strain of ectromelia that encoded an intact 
A26p and did not embed MV into ATIs produced smaller plaques than a strain that 
encoded an intact A26p and embedded MV within ATIs [157]. Small plaque 
phenotypes can be indicative of less EV production, suggesting that occlusion 
sequesters MV from the wrapping pathway. To test this hypothesis, I infected cells 
with vATI+A26+, vATI+A26-, and vA25+A26+ and compared the plaques produced. 
Inclusion body formation did not alter the plaque phenotype on two different cell 
types and, furthermore, occlusion did not result in small plaque formation (Figure 4-
10A).  I also compared EV titers from two cell types infected with vATI+A26+, 
vATI+A26-, and vA25+A26+ and did not find a correlation between EV production 














Figure 4-9:  MV movement dynamics in the absence of A26p. (A) Images of 
tracks in two representative cells are shown statistics-coded by color for speed. Hela 
cells were infected with vA25+A26+- or vA25+A26--.A4:YFP in media containing 10 
µm ST-246 for 7 h, and live imaged at 1.399s/frame in 4D using a Leica SP5 inverted 
microscope with a resonant scanner. Particles were tracked from regions distal from 
virion aggregates using Imaris Spots software. Colorbar, low (red) to high (yellow) 
speeds (µm/s). (B) Bar graphs showing movement dynamics for 1129 and 982 
particle tracks in 4 each vA25+A26+- and vA25+A26--infected cells, respectively. 
Track length is the total length (µm) of recorded movement for each particle. The 
mean speed (µm/s) includes the instantaneous velocities for all particles. Asterisk, P-





The formation of VFs allows orthopoxviruses to coordinate gene expression, 
replication, and assembly [79]. Consequently, viral proteins required for late 
functions are often observed within the VFs. The ATIp is an abundant late protein 
that assembles into large proteinaceous masses called ATIs that are distributed widely 
in the cytoplasm of infected cells. In previous confocal microscopy studies, I did not 
detect ATIp in VFs suggesting either rapid translocation of the protein or an external 
site of ATIp synthesis. In earlier electron microscopic studies polyribosomes were 
detected at the periphery of ATI, consistent with the latter interpretation [153]. Since 
the double stranded DNA genome is located in the VF, these observations suggested a 
model in which the ATIp mRNA is transported out of the VF and translated at the site 
of ATI formation. The subcellular localization of cellular mRNAs has been described 
and there is mounting evidence to indicate the importance of this process [239]. 
To test an mRNA translocation model, I initially monitored ATIp expression 
and inclusion body formation over time in cells infected with a recombinant VACV 
expressing an HA-tagged ATIp. I detected ATIp in small puncti throughout the 
cytoplasm, rather than in VFs, as early as 3 hpi. With time, these puncti enlarged into 
typical ATI. ATIp was never observed as diffuse cytoplasmic staining, unassociated 
with inclusion bodies. To assess whether ATI mRNA is translated at ATIs, I carried 
out three additional experiments. First, I demonstrated that the translation initiation 
factor, eIF4E, was associated with ATIs as well as VFs. Second, a puromycin-
immunodetection assay demonstrated that active translation occurs at the ATI. 




knowledge, this is the first demonstration of an orthopoxvirus late mRNA that is 
transported and translated at specific sites outside of the VF. Presumably the ATIp 
monomers self assemble very rapidly into insoluble aggregates. For this reason, I 
imagine that synthesis of ATIp in the VF would be detrimental to other viral 
processes that take place there.  
To further study ATI formation, I performed quantitative analyses on the 
diameters and mean number of ATIs per cell over the course of infection. I found that 
the mean ATI diameter increased in size from 5 to 11 hpi, whereas the number of 
ATIs decreased. Frequency distributions of ATI diameters revealed that at 5 and 7 
hpi, there was relative uniformity of ATI size. By 9 and 11 hpi, however, there 
existed populations of small, intermediate, and large ATIs. Treatment with CHX 
prevented the emergence of small ATIs at 9 and 11 hpi demonstrating that inclusion 
bodies continuously form throughout infection. More interesting, however, was the 
finding that the size of ATIs increased and the number decreased in the presence of 
CHX, though to a lesser extent than in the absence of the drug. This led us to consider 
that that individual ATI were merging or coalescing. This finding was supported by 
optical sectioning of adjacent ATIs, which in some cases showed a continuum 
between the bodies. To test directly for inclusion body coalescence, PEG was used to 
fuse one cell population expressing an HA-tagged ATIp with another cell population 
expressing an AU1-tagged ATIp. I found that ATI stained for both tags even in the 
presence of CHX, which was added to prevent ATIp monomers synthesized post-cell 
fusion. Anti-HA and -AU1 co-staining was uniform versus patchwork suggesting that 




size of the ATIs, I suspected that the cytoskeleton might be required for their merger. 
I found that the decrease in ATIs was inhibited by nocodazole, implicating 
microtubules in the process. 
 I was also interested in how MVs localize to the ATI. MV movement to ATI 
was investigated using a confocal microscope for live imaging at about 1.57 frames/s. 
Cells were infected with a recombinant VACV expressing the CPXV ATI and the A4 
core protein fused to YFP. ST-246, an inhibitor of MV wrapping, was used to prevent 
movement of WVs on microtubules, which would interfere with our confocal 
microscopy analysis. MV movement was monitored in four dimensions with Z-stacks 
that were typically about 4 µm. Some MVs were observed to associate and then 
disassociate and move away from inclusion bodies. The mean speeds of 4 indivdually 
tracked MVs were similar to mean speeds seen for MV movement to sites of 
wrapping along microtubules [108]. To test whether microtubules are required for 
occlusion, I monitored inclusion bodies for embedment in the presence of 
cytochalasin D and nocodazole, which are drugs that disrupt actin and microtubules, 
respectively. I found that while cytochalasin D did not disrupt occlusion, nocodazole 
drastically reduced the frequency of embedment. 
To date, the viral protein(s) required for MV movement to sites of wrapping 
have not been identified. The A27 protein was initially implicated as an MV-
movement factor [240], but live imaging studies showed that MV of an A27-deletion 
VACV could move bidirectionally between VFs and sites of wrapping. In the absence 
of A27p, A26p is unstable [108], suggesting that A26p is not required for MV 




during occlusion [160]. The primary observation supporting this hypothesis came 
from studies using electron microscopy that showed there exits a visible boundary 
between MV and inclusion bodies in cells infected with viruses expressing ATIp and 
a non-functional A26p [160]. Our finding that A26p is capable of associating with 
inclusion bodies in the absence of virion-anchoring or assembly lent support to the 
idea that A26p might function as a movement protein. Because occlusion requires 
microtubules, I rationalized that if A26p might also use microtubules to actively 
transport to inclusion bodies. However, although the addition of nocodazole to the 
medium of infected cells abrogated occlusion, A26 localization to inclusion bodies 
was not disrupted. 
To further test whether A26p is required for MV movement I compared the 
particle dynamics of an A26-deletion VACV with a VACV encoding an intact A26p 
using live imaging. Cells were infected in the presence of ST-246 to arrest WV 
movement, and particle movement over time was recorded. The number of particles 
moving in cells infected with the A26 deletion VACV appeared similar to the number 
moving in cells infected with wild-type VACV. The deletion of A26 also did not 
affect total track length. However, MV lacking A26p moved with statistically slower 
velocities. One possibility is that within cells there exist two populations of MV. One 
population lacks A26p and moves to sites of wrapping to become EV, and the other 
population has A26p and moves to inclusion bodies using a different motor with 
greater velocities. 
 In early experiments, recombinant strains of CPXV that formed inclusion 




embedded MV in infected cell monolayers [225]. A large plaque phenotype is 
indicative of a greater production of EV, and thus the data suggested that MV were 
sequestered in inclusion bodies from the wrapping pathway. I compared VACV 
expressing the ATI protein in the presence or absence of the occlusion factor, A26p, 
and did not see a difference in plaque phenotype or EV production. It is therefore 
likely that the phenotypic differences in plaque sizes observed previously among the 













Chapter 5:  Conclusions and future directions 
 
 
5.1 Incorporation of A26p into MV 
The A26 protein was of especial interest because it is one of only three known 
MV-specific proteins [145, 241]. A26p lacks a transmembrane domain, and prior to 
this study nothing was known about how it becomes incorporated into the MV 
particle. The instability of A26p in the absence of A27p led us to investigate a 
potential interaction between the two proteins. I found that A26 forms a disulfide-
bonded complex with A27p and this interaction is required for the stability of A26p. 
The A26p-A27p interaction depends on a C-terminal segment of A26p with 45% 
amino acid identity to a region within the A27 protein. The region of homology 
between the two proteins contains two adjacent cysteine residues that were 
subsequently found by another group to be required for the A26p-A27p interaction 
[242]. A27p not only confers stability to A26p but also incorporates it into the viral 
membrane. A27p is anchored to the membrane by a transmembrane protein, A17p 
[123], and I found that A26p interacts with A17p indirectly through the A27p. The 
A27p-A17p complex was thus determined as the anchor for the localization of A26p 
on the surfaces of MVs. One interesting question remaining is the mechanism by 




5.2 A26p-mediated MV embedment into ATIs 
Interestingly, while investigating the mechanism of A26p incorporation into 
MVs, I discovered that the A26p-A27p-A17p complex interacted with the A25 
protein. VACV A25p is also an MV-specific protein [145]. Although the function of 
A25p in VACV is not known, the A25p homolog, ATIp, forms inclusion bodies. 
Some orthopoxviruses, e.g. cowpox and ectromelia viruses, form large, discrete 
cytoplasmic inclusions within which MVs are embedded by a process called 
occlusion. These inclusions are composed of aggregates of the ATIp, and the ATIp 
homolog, A25p, is truncated in orthopoxviruses such as VACV that fail to form 
inclusions [151, 154, 232]. Occlusion requires an intact A26p, and although VACV 
does not form inclusion bodies it encodes a functional A26p [160]. The role of A26p 
in the embedment of MV into ATIs had not been demonstrated prior to this study. As 
discussed above, I showed that A26p is anchored to the MV membrane through 
disulfide bonding with the A27 protein [219, 220], which is in turn tethered to the 
MV membrane through interactions with the A17 transmembrane protein [219]. Our 
discovery that the VACV multiprotein complex A26p-A27p-A17p interacted with 
A25p suggested that it might similarly interact with the intact ATIp, thereby 
embeding MVs in inclusion bodies.  
Given that VACV is the most characterized of the orthopoxviruses, I 
investigated the requirements for occlusion by expressing the CPXV full-length ATIp 
in the VACV background. I found that restoration of the full-length ATI gene was 
sufficient for VACV inclusion formation and the occlusion of MVs. A26p was 




interaction of A26p with ATIp. Analysis of a panel of ATIp mutants indicated that the 
N-terminal domain was required for the interaction with A26p and occlusion and the 
C-terminal repeat region was required for inclusion formation. Interestingly, the N-
terminus of A25p is conserved among orthopoxviruses expressing truncated ATIps. 
The conservation of the N-terminus suggests an additional function for the A25p and 
the A25p-A26p interaction in the virus life cycle. The recent report that A26p and 
A25p cause MV to preferentially enter through fusion within endosomes by 
suppressing fusion at the plasma membrane might be one reason for this conservation 
[243]. The C-terminal truncation of VACV, VARV, and MPXV ATIp homologs 
suggests that the formation of ATIs might be detrimental for these viruses. 
After determining that A26p interacts with ATIp and that this interaction is 
necessary for occlusion I investigated the requirement of A26p-anchoring to the MV 
particle for occlusion. I found that A27p was not needed for association of A26p with 
ATIp, but was indispensable for occlusion. In addition, the C-terminal domain of 
A26p, which mediates A26p-A27p interactions [20, 219, 220], was necessary but 
insufficient for occlusion. The N-terminus of the A26 protein localized to ATIs but as 
shown previously did not associate with A27p or MV. A26p therefore has two 
function domains in occlusion: the N-terminus mediates interactions with ATIp and 
the C-terminus attaches A26p to the MV membrane. Taken together, the data suggest 
a model for occlusion in which A26p has a bridging role between ATIp and A27p, 





5.3 ATI mRNA transport and ATI enlargement 
While studying occlusion, I did not see unincorporated ATIp localized to VFs, 
which prompted us to investigate inclusion body formation. Inclusion body formation 
was previously monitored using electron microscopy and phase contrast microscopy. 
Imaging ATIs formed by our recombinant VACV expressing an HA-tagged ATIp and 
a core protein (A4p) fused to YFP by immunofluorescence confocal microscopy 
achieves greater sensitivity and resolution than phase contrast microscopy, and the 
reconstruction of optical Z-sections gave us a 3D perspective not provided by electron 
microscopy.  
It was reported previously that ATIs form late in infection at ~9-12 hpi [151, 
157, 225], but time course experiments of ATI formation and ATIp synthesis revealed 
that ATIs are dispersed throughout the cytoplasm as early as 3 hpi. Additionally, I did 
not see unincorporated ATIp either in the VFs or the cytoplasm of infected cells. 
Because late transcription occurs in the VF, this suggested to us that ATIp is either 
shuttled rapidly out of VFs or that the ATI mRNA is shuttled out of the VF for 
translation in the cytoplasm at sites of inclusion body nucleation. Supporting the latter 
scenario, previous studies demonstrated the presence of ribosomes at ATI peripheries 
[153]. I localized the translation initiation factor eIF4E, which is also recruited to 
VFs, as well as actively translating ribosomes to the peripheries of inclusion bodies. 
Using FISH, I furthermore determined that the ATI mRNA is associated at the 
peripheries of ATIs. To our knowledge, this is the first report of an orthopoxvirus late 




Orthopoxviruses regulate translation of ATI mRNAs by transporting them out 
of the VF to sites within the cytoplasm. A reason for the translation of ATIp outside 
of VFs could be the hydrophobic properties of the protein, which cause it to assemble 
into insoluble aggregates that might perturb other processes in the VF. Given the 
abundance of ATIp, perhaps ATI mRNA is segregated to prevent depletion of 
resources necessary for the translation of other late viral proteins. Additionally, 
perhaps the polyribosomes at the ATI periphery function in amplifying translation of 
the ATI mRNA message for rapid assembly. 
An exciting future project would be to study the requirements of ATI mRNA 
transport from the VFs to sites in the cytoplasm. To this end, I could use the 
bacteriophage MS2-GFP system. The coat protein is fused to GFP (MS2-GFP) and 
selectively binds hairpin RNAs. These hairpins can be engineered into a gene of 
interest and coexpressed with MS2-GFP in cells for live tracking of individual 
mRNAs. It would be of interest to demonstrate directly the transport of ATI mRNA 
from VFs to the cytoplasm. This system could also be used to define ATI mRNA 
sequences and host factors involved in the transport of ATI mRNA. It is likely the 
ATI mRNA contains a ‘cis-acting element’ or zipcode recognized by mRNA binding 
proteins for transport out of the VF [244]. Typically, zipcodes are found in the 3’ and 
5’ UTRs of mRNAs. One method to identify zipcodes is by using antisense 
oligonucleotides targeting specific sequences within the mRNA and then to look for 
the mislocalization of those mRNAs.   
It would be interesting to identify the RNA binding partners and motor 




that shuttle ATI mRNAs out of the VF use motor proteins to move along the 
cytoskeleton to specific sites in the cytoplasm [245]. To identify the motor protein 
that transports ATI mRNAs, one could use dominant negative inhibitors of motor 
proteins and look for mislocalization of the ATI mRNA. Interestingly, in pilot 
experiments studying the effects of kinesin-1 and dynein dominant negative inhibitors 
on occlusion, I noted that the kinesin-1 inhibitor, which competes with cargo for 
kinesin-1 binding, localized within inclusion bodies but the dynein inhibitor did not 
(data not shown). 
The time course of ATI formation revealed that ATIs enlarge over time as 
previously reported, and enlargement requires new protein synthesis. Interestingly, 
enlargement of ATIs corresponded to a decrease in ATI number in the presence of 
CHX. This suggested that ATIs were enlarging by merging together or coalescing. 
Supporting this notion, I observed continua between adjacent ATIs by fixed cell 
microscopy. Pegylation experiments fusing separate cell populations each expressing 
an ATIp with a different tag revealed ATIs expressing both tags in multinucleated 
cell clusters even in the presence of CHX. The staining of the tags was uniform rather 
than patchwork suggesting that ATI coalescence results in content mixing between 
ATIs rather than aggregation. Although the matrices of ATIs are selective, content 
mixing among ATIs suggests that they are also fluid. The role of coalescence is not 
clear, but I observed by live imaging that MVs appeared to be transferred between 
two coalescing inclusion bodies.  
Given the size of ATIs, it was likely that the cytoskeleton is required for their 




which suggests that ATIs are motile bodies. ATIs appeared by live imaging as 
dynamic structures that exhibited a rolling motion. The movement of large protein 
aggregates along microtubules is reminiscent of the formation of cellular aggresomes. 
Protein aggregates of misfolded proteins between ~4 and 50 nm use dynein motors 
for retrograde movement along microtubules to the microtubule-organizing center 
(MTOC) where they coalesce and become surrounded by vimentin cages that 
immobilize them for proteasome-mediated degradation [246]. Interestingly, vimentin 
collapses to form cages around VFs during VACV infections [247]. I did not, 
however, observe vimentin cages surrounding ATIs (data not shown). 
 
5.4 Role of A26p in MV movement and wrapping 
Electron micrographs from a previous study showed small masses of granular 
material thought to be newly forming ATIs associated with MVs and polyribosomes. 
This observation led authors to suggest that MVs might nucleate the formation of 
ATIs [153]. Contradictory to this notion, ATIs still form when A26p is truncated and 
MVs do not become embedded. Additionally, ATIs formed in the presence of the 
drug rifampicin, which blocks virion assembly but not late protein synthesis, and 
ATIs were dispersed in the cytoplasm by 3 hpi, prior to MV assembly and the 
subsequent movement out of the VFs. Since ATIs do not nucleate around MVs, it 
suggested MVs must localize to ATIs for embedment. Given the distance of ATIs 
from VFs and the large size of MV (~360 X 270 X 250 nm), it was likely that the 
localization of MV to ATIs required active transport along the cytoskeleton. Using 




microtubules for embedment within inclusion bodies. I also observed using live 
imaging that the MVs moved to inclusion bodies at speeds similar to those observed 
in the movement of MVs to sites of wrapping [108]. 
McKelvey et al. proposed that A26p might be a movement protein that 
transports MV from VFs to ATIs during occlusion [160]. In the absence of intact 
A26p, electron microscopy reveals that there exists a spatial separation between MVs 
and ATIs [160]. This suggests MVs that do not have intact A26p do not move ATIs. 
Further support for a role of A26p in MV movement to ATIs came from our finding 
that A26p associates with inclusion bodies in the absence of virus assembly or 
anchoring to the MV particle. This finding implied that A26p might move along 
microtubules independently from other viral proteins. Because microtubules were 
required for occlusion, I investigated the dependence of microtubules for A26p 
localization. I found that A26p associated with ATIs even in the presence of 
nocodazole suggesting that A26p localizes to ATIs by passive diffusion.  
Our finding that A26p is unstable in the absence of A27p, suggested that 
A26p is dispensable for MV movement. The A27 protein was initially implicated as 
an MV-movement factor [240], but live imaging studies showed that MV of an A27-
deletion VACV could move bidirectionally between VFs and sites of wrapping. 
Nevertheless, although A26p does not move independently of the virus, it is possible 
that A26p might contribute to movement. For example, the VACV F12 and A36 
proteins cooperate in the egress of WVs. F12p binds the kinesin-1 motor for 
movement along microtubules but requires A36p for anchoring to the WV membrane 




A26p in MV movement, I examined MV particle dynamics in the absence of A26p to 
see if I could detect a defect in movement. Using live imaging, I compared the 
movement dynamics of wild-type VACV and A26 deletion VACV MVs and found 
that a similar number of particles moved for each virus. However, interestingly, MVs 
lacking A26p moved with statistically slower velocities. 
The significance of the defect in MV speeds in the absence of A26p is 
unclear. I could speculate that within cells there exist two populations of MVs. One 
population lacks A26p and moves to sites of wrapping to become EVs, and the other 
population has A26p and moves to inclusion bodies using a different motor that 
moves with greater velocities. Analogously, VACV MVs lacking A26p would move 
to sites of wrapping, whereas, MVs containing A26p would move away from sites of 
wrapping for retention in the cell until lysis. The specificity of A26p for MV 
membranes makes it an attractive candidate for the negative regulation of wrapping 
either as a directional movement protein or in some other capacity. Toward the latter, 
it is possible that MVs containing A26p move to sites of wrapping but are excluded 
from the wrapping pathway. This is plausible since A27 is required for EV formation 
[248], and A26p interacts with A27p but is excluded from EVs. It has been suggested 
that A27p mediates wrapping by interacting with either a viral protein such as F13p 
or with a host protein at the wrapping proteins for wrapping. The finding that an 
ECTV strain that embeds MVs within ATIs forms smaller plaques than a strain that 
encodes a truncated A26p and does not embed MVs within ATIs suggested that 
occlusion might represent an oppositional fate to wrapping and further implicated 




Taken together, the potential role of A26p in MV movement, the exclusion of 
A26p from wrapped particles, and its association with the wrapping protein, A27p, 
suggested A26p might negatively regulate wrapping. However, the deletion of VACV 
A26L did not affect the plaque phenotype in two cell lines. Moreover, when I titered 
the EVs released in the cell media, I did not detect an increase in their production. 
Similarly, recombinant VACVs expressing the ATIp in the presence of A26p did not 
produce smaller plaques than recombinant VACVs expressing ATIp but with a 
deleted A26L gene. The simplest interpretation is that A26p does not have a role in 
the differentiation of MVs into EVs either as a movement factor or by some other 
mechanism. However, I did not measure the production of WVs in the absence of 
A26p, and it is possible that more WVs were produced but not released as EVs. EV 
production could be limited by other factors such as the availability of wrapping 
membranes, viral proteins, and other host proteins required for egress and release. I 
did find a reduction in EV production when A26p was overexpressed, but this was 
correlated with a reduction in the expression of other viral proteins, including A27p, 
and was therefore difficult to interpret (our unpublished data).  
An interesting question is how A26p becomes excluded from EV/CEVs. The 
A27p-A17p complex is found in MV, WV, and EV/CEV particles, however A26p is 
only found in MVs. There are three main scenarios of exclusion that seem likely: (1) 
MVs containing A26p do not move to sites of wrapping, (2) MVs containing A26p 
move to sites of wrapping but do not become wrapped, or (3) A26p is removed from 
MVs at sites of wrapping. It is unknown whether A26p is present at sites of wrapping, 




that were A26p present at sites of wrapping it would be highly transitory and difficult 
to detect by methods such as immunogold labeling electron microscopy or fixed cell 
microscopy. If MV containing A26p moved to sites of wrapping and failed to wrap as 
is proposed in scenario two, it is unlikely that they would accumulate because MVs 
have been observed to move bidirectionally between VFs and sites of wrapping. In 
the third scenario, A26p would likely not be detectable because it is unstable when 
not associated with the A27 protein. Therefore, the most plausible method would be 
to monitor the localization of MV containing A26p relative to sites of wrapping using 
live imaging confocal microscopy.  
The wrapping membrane protein, B5p, is functional as a GFP fusion protein 
[131, 249]. Were A26p to be functional as a fusion protein, I could simultaneously 
track the core (A4p:YFP), A26p (A26p:mCherry), and B5p (B5p:CFP) while using a 
DNA marker to monitor for coincidence at VFs and sites of wrapping. This technique 
could also be applied to further investigate a role for A26p in MV movement. I could 
not only localize MVs containing A26p but also compare the particle dynamics of 
MVs that have or do not have A26p. In general, the generation of a recombinant 
VACV expressing an A26p:fluorescent protein would be effective tool in other 
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